TY  - JOUR
AU  - Filipić, Brankica
AU  - Ušjak, Dušan
AU  - Hrast Rambaher, Martina
AU  - Oljačić, Slavica
AU  - Milenković, Marina
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5574
AB  - Antimicrobial resistance is a global threat, leading to an alarming increase in the prevalence of bacterial infections that can no longer be treated with available antibiotics. The World Health Organization estimates that by 2050 up to 10 million deaths per year could be associated with antimicrobial resistance, which would equal the annual number of cancer deaths worldwide. To overcome this emerging crisis, novel anti-bacterial compounds are urgently needed. There are two possible approaches in the fight against bacterial infections: a) targeting structures within bacterial cells, similar to existing antibiotics; and/or b) targeting virulence factors rather than bacterial growth. Here, for the first time, we provide a comprehensive overview of the key steps in the evaluation of potential new anti-bacterial and/or anti-virulence compounds. The methods described in this review include: a) in silico methods for the evaluation of novel compounds; b) anti-bacterial assays (MIC, MBC, Time-kill); b) anti-virulence assays (anti-biofilm, anti-quorum sensing, anti-adhesion); and c) evaluation of safety aspects (cytotoxicity assay and Ames test). Overall, we provide a detailed description of the methods that are an essential tool for chemists, computational chemists, microbiologists, and toxicologists in the evaluation of potential novel antimicrobial compounds. These methods are cost-effective and have high predictive value. They are widely used in preclinical studies to identify new molecular candidates, for further investigation in animal and human trials.
PB  - Frontiers Media SA
T2  - Frontiers in Cellular and Infection Microbiology
T1  - Evaluation of novel compounds as anti-bacterial or anti-virulence agents
VL  - 14
DO  - 10.3389/fcimb.2024.1370062
ER  - 

@article{
author = "Filipić, Brankica and Ušjak, Dušan and Hrast Rambaher, Martina and Oljačić, Slavica and Milenković, Marina",
year = "2024",
abstract = "Antimicrobial resistance is a global threat, leading to an alarming increase in the prevalence of bacterial infections that can no longer be treated with available antibiotics. The World Health Organization estimates that by 2050 up to 10 million deaths per year could be associated with antimicrobial resistance, which would equal the annual number of cancer deaths worldwide. To overcome this emerging crisis, novel anti-bacterial compounds are urgently needed. There are two possible approaches in the fight against bacterial infections: a) targeting structures within bacterial cells, similar to existing antibiotics; and/or b) targeting virulence factors rather than bacterial growth. Here, for the first time, we provide a comprehensive overview of the key steps in the evaluation of potential new anti-bacterial and/or anti-virulence compounds. The methods described in this review include: a) in silico methods for the evaluation of novel compounds; b) anti-bacterial assays (MIC, MBC, Time-kill); b) anti-virulence assays (anti-biofilm, anti-quorum sensing, anti-adhesion); and c) evaluation of safety aspects (cytotoxicity assay and Ames test). Overall, we provide a detailed description of the methods that are an essential tool for chemists, computational chemists, microbiologists, and toxicologists in the evaluation of potential novel antimicrobial compounds. These methods are cost-effective and have high predictive value. They are widely used in preclinical studies to identify new molecular candidates, for further investigation in animal and human trials.",
publisher = "Frontiers Media SA",
journal = "Frontiers in Cellular and Infection Microbiology",
title = "Evaluation of novel compounds as anti-bacterial or anti-virulence agents",
volume = "14",
doi = "10.3389/fcimb.2024.1370062"
}

Filipić, B., Ušjak, D., Hrast Rambaher, M., Oljačić, S.,& Milenković, M.. (2024). Evaluation of novel compounds as anti-bacterial or anti-virulence agents. in Frontiers in Cellular and Infection Microbiology
Frontiers Media SA., 14.
https://doi.org/10.3389/fcimb.2024.1370062

Filipić B, Ušjak D, Hrast Rambaher M, Oljačić S, Milenković M. Evaluation of novel compounds as anti-bacterial or anti-virulence agents. in Frontiers in Cellular and Infection Microbiology. 2024;14.
doi:10.3389/fcimb.2024.1370062 .

Filipić, Brankica, Ušjak, Dušan, Hrast Rambaher, Martina, Oljačić, Slavica, Milenković, Marina, "Evaluation of novel compounds as anti-bacterial or anti-virulence agents" in Frontiers in Cellular and Infection Microbiology, 14 (2024),
https://doi.org/10.3389/fcimb.2024.1370062 . .

TY  - JOUR
AU  - Filipić, Brankica
AU  - Rapajić-Moran, Ivana
AU  - Nikolić, Ines
AU  - Oljačić, Slavica
AU  - Mandić, Aljoša
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5580
AB  - Human papillomaviruses (HPV) are the most common sexually transmitted pathogens
worldwide, leading to infections with a wide range of clinical manifestations: from benign
conditions to different types of cancer in women and men as well. Cervical cancer is highly
correlated with persistent high-risk-HPV (HR-HPV) infection, which is the key factor in
emergence of 99.99% of cervical cancer cases. The most effective way to prevent HPV-related
cancers is vaccination. There are three available prophylactic HPV vaccines: bivalent,
quadrivalent and nonavalent. The nonavalent vaccine is gradually replacing other HPV vaccines
in most countries and can be given from year 9, but it is commonly routinely implemented at the
age of 11 to 12. The World Health Organization has recognised cervical cancer as a global threat
and has announced the so-called 90-70-90 strategy to reduce and even eliminate cervical cancer.
This strategy implies that 90% of girls should be vaccinated by the age of 15, 70% of women
should be screened for cervical cancer, and 90% of women diagnosed with cervical disease should
receive adequate treatment. Although different treatment options are available: surgery, radiation
therapy, chemotherapy, and advanced target therapy using monoclonal antibodies, great efforts
are needed to achieve the goals set by the World Health Organization to eliminate cervical cancer.
AB  - Humani papilomavirusi (HPV) su među najčešćim uzročnicima seksualno prenosivih patogena i mogu dovesti do različitih kliničkih manifestacija: od benignih stanja do različitih vrsta karcinoma kod žena, ali i muškaraca. Najčešći HPV-posredovan karcinom je karcinom grlića materice koji je u preko 99,99% slučajeva posledica infekcije. Najefikasniji način da se spreči razvoj perzistentne HR-HPV infekcije je vakcinacija. Dostupne su tri profilaktičke vakcine: dvovalentna, kvadrivalentna i devetovalentna. Devetovalentna vakcina pruža najširu zaštitu jer sadrži devet onkogenih HPV genotipova i postepeno zamenjuje ostale vakcine u svim zemljama. Sa vakcinacijom se može krenuti od 9. godine, ali se najčešće rutinski sprovodi kod dečaka i devojčica u uzrastu od 11 do 12 godina. Svetska zdravstvena organizacija je prepoznala karcinom grlića materice kao globalni problem i uvela takozvanu 90-70-90 strategiju u cilju smanjenja stope, pa čak i eliminacije karcinoma grlića materice. Ova strategija podrazumeva da 90% devojčica bude potpuno vakcinisano do 15. godine, 70% žena pristupi redovnom ginekološkom pregledu do 35. godine i ponovo do 45. godine i 90% žena sa promenama na grliću materice primi adekvatnu terapiju. Iako su dostupne različite terapije poput hirurškog tretmana, radioterapije, hemioterapije i ciljane terapije monoklonskim antitelima, i dalje su potrebni veliki napori da bi se dostigli ciljevi Svetske zdravstvene organizacije.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Human papillomaviruses and cervical cancer from the perspective of the World Health Organisation initiative for cervical cancer elimination
T1  - Humani papilomavirusi i karcinom grlića materice iz perspektive inicijative Svetske zdravstvene organizacije za eliminaciju karcinoma grlića materice
VL  - 74
IS  - 1
SP  - 56
EP  - 75
DO  - 10.5937/arhfarm74-48226
ER  - 

@article{
author = "Filipić, Brankica and Rapajić-Moran, Ivana and Nikolić, Ines and Oljačić, Slavica and Mandić, Aljoša",
year = "2024",
abstract = "Human papillomaviruses (HPV) are the most common sexually transmitted pathogens
worldwide, leading to infections with a wide range of clinical manifestations: from benign
conditions to different types of cancer in women and men as well. Cervical cancer is highly
correlated with persistent high-risk-HPV (HR-HPV) infection, which is the key factor in
emergence of 99.99% of cervical cancer cases. The most effective way to prevent HPV-related
cancers is vaccination. There are three available prophylactic HPV vaccines: bivalent,
quadrivalent and nonavalent. The nonavalent vaccine is gradually replacing other HPV vaccines
in most countries and can be given from year 9, but it is commonly routinely implemented at the
age of 11 to 12. The World Health Organization has recognised cervical cancer as a global threat
and has announced the so-called 90-70-90 strategy to reduce and even eliminate cervical cancer.
This strategy implies that 90% of girls should be vaccinated by the age of 15, 70% of women
should be screened for cervical cancer, and 90% of women diagnosed with cervical disease should
receive adequate treatment. Although different treatment options are available: surgery, radiation
therapy, chemotherapy, and advanced target therapy using monoclonal antibodies, great efforts
are needed to achieve the goals set by the World Health Organization to eliminate cervical cancer., Humani papilomavirusi (HPV) su među najčešćim uzročnicima seksualno prenosivih patogena i mogu dovesti do različitih kliničkih manifestacija: od benignih stanja do različitih vrsta karcinoma kod žena, ali i muškaraca. Najčešći HPV-posredovan karcinom je karcinom grlića materice koji je u preko 99,99% slučajeva posledica infekcije. Najefikasniji način da se spreči razvoj perzistentne HR-HPV infekcije je vakcinacija. Dostupne su tri profilaktičke vakcine: dvovalentna, kvadrivalentna i devetovalentna. Devetovalentna vakcina pruža najširu zaštitu jer sadrži devet onkogenih HPV genotipova i postepeno zamenjuje ostale vakcine u svim zemljama. Sa vakcinacijom se može krenuti od 9. godine, ali se najčešće rutinski sprovodi kod dečaka i devojčica u uzrastu od 11 do 12 godina. Svetska zdravstvena organizacija je prepoznala karcinom grlića materice kao globalni problem i uvela takozvanu 90-70-90 strategiju u cilju smanjenja stope, pa čak i eliminacije karcinoma grlića materice. Ova strategija podrazumeva da 90% devojčica bude potpuno vakcinisano do 15. godine, 70% žena pristupi redovnom ginekološkom pregledu do 35. godine i ponovo do 45. godine i 90% žena sa promenama na grliću materice primi adekvatnu terapiju. Iako su dostupne različite terapije poput hirurškog tretmana, radioterapije, hemioterapije i ciljane terapije monoklonskim antitelima, i dalje su potrebni veliki napori da bi se dostigli ciljevi Svetske zdravstvene organizacije.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Human papillomaviruses and cervical cancer from the perspective of the World Health Organisation initiative for cervical cancer elimination, Humani papilomavirusi i karcinom grlića materice iz perspektive inicijative Svetske zdravstvene organizacije za eliminaciju karcinoma grlića materice",
volume = "74",
number = "1",
pages = "56-75",
doi = "10.5937/arhfarm74-48226"
}

Filipić, B., Rapajić-Moran, I., Nikolić, I., Oljačić, S.,& Mandić, A.. (2024). Human papillomaviruses and cervical cancer from the perspective of the World Health Organisation initiative for cervical cancer elimination. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 74(1), 56-75.
https://doi.org/10.5937/arhfarm74-48226

Filipić B, Rapajić-Moran I, Nikolić I, Oljačić S, Mandić A. Human papillomaviruses and cervical cancer from the perspective of the World Health Organisation initiative for cervical cancer elimination. in Arhiv za farmaciju. 2024;74(1):56-75.
doi:10.5937/arhfarm74-48226 .

Filipić, Brankica, Rapajić-Moran, Ivana, Nikolić, Ines, Oljačić, Slavica, Mandić, Aljoša, "Human papillomaviruses and cervical cancer from the perspective of the World Health Organisation initiative for cervical cancer elimination" in Arhiv za farmaciju, 74, no. 1 (2024):56-75,
https://doi.org/10.5937/arhfarm74-48226 . .

TY  - JOUR
AU  - Gojković, Tamara
AU  - Vladimirov, Sandra
AU  - Antonić, Tamara
AU  - Bogavac-Stanojević, Nataša
AU  - Novović, Katarina
AU  - Spasojević-Kalimanovska, Vesna
AU  - Filipić, Brankica
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5421
AB  - Background: The pre-analytical (PA) phase is the most vulnerable phase of laboratory testing procedure, with critical procedures-collection, handling, sample transport, and time and temperature of sample storage. The aim of this study was to examine if different anticoagulants, storage conditions, and freeze-thaw cycles (FTCs) influence the concentrations of basic biochemical parameters. In parallel, the presence and the effect of sample microbiological contamination during routine laboratory work were examined.

Methods: Two plasma pools (EDTA, and sodium-fluoride/potassium oxalate plasma (NaF)) were stored at +4C˚/-20˚C. Total cholesterol (TC), glucose, triglycerides (TG), urea, total protein (TP), and albumin concentrations were measured using Ilab 300+. Sample microbiological contamination was determined by 16S rRNA sequence analysis. The experiment encompassed a 5 day-period: Day 1–fresh sample, Day 2–1st FTC, Day 3–2nd FTC, Day 4–3rd FTC, Day 5–4th FTC. The appearance of bacteria in two consecutive samples was the experiment's endpoint.

Results: During 4 FTCs there were no changes in plasma urea concentrations. Glucose was stable in EDTA+4˚C and NaF- 20˚C until the 3rd FTC (P=0.008, P=0.042, respectively). Changes in protein concentrations followed the zig-zag pattern. TG concentrations changed significantly in the EDTA-20˚C sample after 1st and 4th FTCs (P=0.022, P=0.010, respectively). In NaF samples no contamination was observed during 4 FTCs.

 

Conclusions: Urea and glucose concentrations were robust. Changes in lipid and protein concentrations after FTCs follow complex patterns. Bacterial growth was not observed in NaF plasma samples. This can promote NaF use in analytical procedures in which microbiological contamination affects the quality of analysis.
AB  - Uvod: Preanaliti~ka (PA) faza je slo`en proces koji ~ine:
prikupljanje, rukovanje, transport i skladi{tenje uzoraka, i
predstavlja najzna~ajniji izvor laboratorijskih gre{aka. Cilj
ovog istra`ivanja je bio da se ispita stabilnost osnovnih
biohemijskih parametara u zavisnosti od uslova skladi{tenja
uzoraka i broja ciklusa zamrzavanja-odmrzavanja (FTC).
Pored toga, ispitivano je prisustvo bakterijske kontaminacije
uzoraka tokom rutinskog laboratorijskog rada.
Metode: Dva »pool«-a plazme (etilendiaminotetrasir}etna
kiselina (EDTA) i natrijum-fluorid/kalijum oksalat (NaF)) su
skladi{tena na +4 ˚C/-20 ˚C. Koncentracije ukupnog
holesterola (TC), glukoze, triglicerida (TG), uree i albumina
su odre|ene kori{}enjem BioSystems reagenasa (holesterol
oksidaza/peroksidaza, glukoza oksidaza/peroksidaza,
glice rol fosfat oksidaza/peroksidaza, ureaza/salicilat, od-
nosno bromkrezol zeleno metodama, sukcesivno) na Ilab
300+ analizatoru. Bakterijska kontaminacija uzoraka je
potvr|ena 16S rRNA sekvencioniranjem. Eksperiment je
sproveden tokom 5 uzastopnih dana: 1. dan – sve` uzorak,
2. dan – 1. FTC, 3. dan –2. FTC, 4. dan – 3. FTC, 5. dan
– 4. FTC. Zavr{nu ta~ku eksperimenta predstavljala je
pojava bakterija u dva uzastopna uzorka.
Rezultati: Tokom 4 FTC koncentracije uree u plazmi se nisu
zna~ajno razlikovale. Koncentracija glukoze je bila stabilna
u EDTA +4 ˚C i NaF -20 ˚C do 3.FTC (P=0,008,
P=0,042, redom). Koncentracije TG su se zna~ajno pro-
menile u uzorku EDTA -20 ˚C nakon 1. i 4. FTC-a (P=0,022, P=0,010, redom). U uzorcima NaF plazme
nije do{lo do bakterijske kontaminacije tokom 4. FTC.
Zaklju~ak: Koncentracije uree i glukoze su bile stabilne
tokom trajanja eksperimenta. Promene u koncentracijama
lipida nakon FTC prate slo`ene obrasce. Rast bakterija nije
prime}en u uzorcima NaF plazme, te upotreba ovog anti-
koagulansa mo`e biti opravdana u analiti~kim proce -
durama podlo`nim uticaju mikrobiolo{ke kontaminacije.
PB  - Journal of Medical Biochemistry
T2  - Journal of Medical Biochemistry
T1  - The influence of various sample storage conditions and sample microbial contamination on concentrations of routine biochemical parameters
T1  - Uticaj različitih uslova čuvanja uzoraka i kontaminacije uzoraka bakterijama na koncentracije rutinskih biohemijskih parametara
VL  - 43
IS  - 1
DO  - https://doi.org/10.5937/jomb0-40360
ER  - 

@article{
author = "Gojković, Tamara and Vladimirov, Sandra and Antonić, Tamara and Bogavac-Stanojević, Nataša and Novović, Katarina and Spasojević-Kalimanovska, Vesna and Filipić, Brankica",
year = "2023",
abstract = "Background: The pre-analytical (PA) phase is the most vulnerable phase of laboratory testing procedure, with critical procedures-collection, handling, sample transport, and time and temperature of sample storage. The aim of this study was to examine if different anticoagulants, storage conditions, and freeze-thaw cycles (FTCs) influence the concentrations of basic biochemical parameters. In parallel, the presence and the effect of sample microbiological contamination during routine laboratory work were examined.

Methods: Two plasma pools (EDTA, and sodium-fluoride/potassium oxalate plasma (NaF)) were stored at +4C˚/-20˚C. Total cholesterol (TC), glucose, triglycerides (TG), urea, total protein (TP), and albumin concentrations were measured using Ilab 300+. Sample microbiological contamination was determined by 16S rRNA sequence analysis. The experiment encompassed a 5 day-period: Day 1–fresh sample, Day 2–1st FTC, Day 3–2nd FTC, Day 4–3rd FTC, Day 5–4th FTC. The appearance of bacteria in two consecutive samples was the experiment's endpoint.

Results: During 4 FTCs there were no changes in plasma urea concentrations. Glucose was stable in EDTA+4˚C and NaF- 20˚C until the 3rd FTC (P=0.008, P=0.042, respectively). Changes in protein concentrations followed the zig-zag pattern. TG concentrations changed significantly in the EDTA-20˚C sample after 1st and 4th FTCs (P=0.022, P=0.010, respectively). In NaF samples no contamination was observed during 4 FTCs.

 

Conclusions: Urea and glucose concentrations were robust. Changes in lipid and protein concentrations after FTCs follow complex patterns. Bacterial growth was not observed in NaF plasma samples. This can promote NaF use in analytical procedures in which microbiological contamination affects the quality of analysis., Uvod: Preanaliti~ka (PA) faza je slo`en proces koji ~ine:
prikupljanje, rukovanje, transport i skladi{tenje uzoraka, i
predstavlja najzna~ajniji izvor laboratorijskih gre{aka. Cilj
ovog istra`ivanja je bio da se ispita stabilnost osnovnih
biohemijskih parametara u zavisnosti od uslova skladi{tenja
uzoraka i broja ciklusa zamrzavanja-odmrzavanja (FTC).
Pored toga, ispitivano je prisustvo bakterijske kontaminacije
uzoraka tokom rutinskog laboratorijskog rada.
Metode: Dva »pool«-a plazme (etilendiaminotetrasir}etna
kiselina (EDTA) i natrijum-fluorid/kalijum oksalat (NaF)) su
skladi{tena na +4 ˚C/-20 ˚C. Koncentracije ukupnog
holesterola (TC), glukoze, triglicerida (TG), uree i albumina
su odre|ene kori{}enjem BioSystems reagenasa (holesterol
oksidaza/peroksidaza, glukoza oksidaza/peroksidaza,
glice rol fosfat oksidaza/peroksidaza, ureaza/salicilat, od-
nosno bromkrezol zeleno metodama, sukcesivno) na Ilab
300+ analizatoru. Bakterijska kontaminacija uzoraka je
potvr|ena 16S rRNA sekvencioniranjem. Eksperiment je
sproveden tokom 5 uzastopnih dana: 1. dan – sve` uzorak,
2. dan – 1. FTC, 3. dan –2. FTC, 4. dan – 3. FTC, 5. dan
– 4. FTC. Zavr{nu ta~ku eksperimenta predstavljala je
pojava bakterija u dva uzastopna uzorka.
Rezultati: Tokom 4 FTC koncentracije uree u plazmi se nisu
zna~ajno razlikovale. Koncentracija glukoze je bila stabilna
u EDTA +4 ˚C i NaF -20 ˚C do 3.FTC (P=0,008,
P=0,042, redom). Koncentracije TG su se zna~ajno pro-
menile u uzorku EDTA -20 ˚C nakon 1. i 4. FTC-a (P=0,022, P=0,010, redom). U uzorcima NaF plazme
nije do{lo do bakterijske kontaminacije tokom 4. FTC.
Zaklju~ak: Koncentracije uree i glukoze su bile stabilne
tokom trajanja eksperimenta. Promene u koncentracijama
lipida nakon FTC prate slo`ene obrasce. Rast bakterija nije
prime}en u uzorcima NaF plazme, te upotreba ovog anti-
koagulansa mo`e biti opravdana u analiti~kim proce -
durama podlo`nim uticaju mikrobiolo{ke kontaminacije.",
publisher = "Journal of Medical Biochemistry",
journal = "Journal of Medical Biochemistry",
title = "The influence of various sample storage conditions and sample microbial contamination on concentrations of routine biochemical parameters, Uticaj različitih uslova čuvanja uzoraka i kontaminacije uzoraka bakterijama na koncentracije rutinskih biohemijskih parametara",
volume = "43",
number = "1",
doi = "https://doi.org/10.5937/jomb0-40360"
}

Gojković, T., Vladimirov, S., Antonić, T., Bogavac-Stanojević, N., Novović, K., Spasojević-Kalimanovska, V.,& Filipić, B.. (2023). The influence of various sample storage conditions and sample microbial contamination on concentrations of routine biochemical parameters. in Journal of Medical Biochemistry
Journal of Medical Biochemistry., 43(1).
https://doi.org/https://doi.org/10.5937/jomb0-40360

Gojković T, Vladimirov S, Antonić T, Bogavac-Stanojević N, Novović K, Spasojević-Kalimanovska V, Filipić B. The influence of various sample storage conditions and sample microbial contamination on concentrations of routine biochemical parameters. in Journal of Medical Biochemistry. 2023;43(1).
doi:https://doi.org/10.5937/jomb0-40360 .

Gojković, Tamara, Vladimirov, Sandra, Antonić, Tamara, Bogavac-Stanojević, Nataša, Novović, Katarina, Spasojević-Kalimanovska, Vesna, Filipić, Brankica, "The influence of various sample storage conditions and sample microbial contamination on concentrations of routine biochemical parameters" in Journal of Medical Biochemistry, 43, no. 1 (2023),
https://doi.org/https://doi.org/10.5937/jomb0-40360 . .

TY  - JOUR
AU  - Nikolić, Ines
AU  - Filipić, Brankica
AU  - Marija Petrović
AU  - Jordan, Olivier
AU  - Savić, Snežana
AU  - Borchard, Gerrit
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5358
AB  - The field of nanotechnology is at the forefront of a scientific revolution, where the term
“nano” transcends mere size and opens the door to enormous possibilities.
In the context of drug development, the selection of a suitable drug delivery system
(corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly,
nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining
recognition for addressing healthcare issues.
While these products hold immense promise, they have faced certain complexities in their
translation from the preclinical to the clinical setting, reflected in the lack of proper assessment
protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory
environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of
liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory
approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in
the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their
significance. However, the relatively modest number of approved nanomedicines compared to the
extensive research efforts raises important questions and underscores areas of uncertainty.
This article provides an overview of the challenges in defining nanomedicines, their
properties, the complexities of regulatory frameworks, and the imperative for standardized
characterization protocols.
AB  - Polje nanotehnologije se nalazi na čelu naučne revolucije, gde se termin "nano" izdiže iznad pukog označavanja veličine, otvarajući vrata novim mogućnostima. U kontekstu razvoja lekova, izbor odgovarajućeg sistema za isporuku / nosača (koji odgovara određenoj aktivnoj supstanci) predstavlja ključnu odluku. U tom kontekstu, nanosistemi već određeno vreme predstavljaju inovativna rešenja. Iako farmaceutski nanosistemi nose ogroman potencijal, suočavaju se sa određenim izazovima u pogledu translacije sa prekliničkog na klinički nivo, što se ogleda u nedostatku odgovarajućih protokola za ispitivanje kvaliteta i bezbednosti i, shodno tome, nedefinisanom regulatornom okruženju. Od revolucionarnog odobrenja liposomalnog doksorubicina od strane Američke agencije za hranu i lekove 1995. godine, pa sve do danas, oko 80 nano formulacija (nanolekova) odobreno je za kliničku primenu. Odnedavno je intenzivnija pažnja usmerena ka nanoformulacijama baziranim na lipidima, što je delom posledica razvoja mRNK vakcina tokom pandemije COVID-19. Međutim, relativno skroman nastup nanolekova na tržištu (u poređenju sa obimnim istraživačkim naporima i finansijskim ulaganjima u ovu oblast) otvara važna pitanja. Ovaj rad pruža pregled izazova u definisanju nanolekova, njihovih svojstava, kompleksnosti regulatornih okvira i imperativa za stvaranje standardizovanih protokola karakterizacije.
PB  - Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - The Landscape of Nanomedicines: An Expert Perspective
T1  - "Pejzažni" prikaz nanolekova - ekspertska perspektiva
VL  - 73
IS  - 5
SP  - 390
EP  - 403
DO  - 10.5937/arhfarm73-46686
ER  - 

@article{
author = "Nikolić, Ines and Filipić, Brankica and Marija Petrović and Jordan, Olivier and Savić, Snežana and Borchard, Gerrit",
year = "2023",
abstract = "The field of nanotechnology is at the forefront of a scientific revolution, where the term
“nano” transcends mere size and opens the door to enormous possibilities.
In the context of drug development, the selection of a suitable drug delivery system
(corresponding to a certain active pharmaceutical ingredient) is a pivotal decision. Accordingly,
nanosystems have emerged as a promising avenue, offering innovative solutions, and gaining
recognition for addressing healthcare issues.
While these products hold immense promise, they have faced certain complexities in their
translation from the preclinical to the clinical setting, reflected in the lack of proper assessment
protocols for quality and safety aspects and, consequently, an insufficiently defined regulatory
environment. Since the groundbreaking US Food and Drug Administration (FDA) approval of
liposomal doxorubicin in 1995, approximately 80 nanomedicine products have received regulatory
approval so far. Recent attention has gravitated toward lipid-based nanomedicines, particularly in
the development of mRNA vaccines during the COVID-19 pandemic, further highlighting their
significance. However, the relatively modest number of approved nanomedicines compared to the
extensive research efforts raises important questions and underscores areas of uncertainty.
This article provides an overview of the challenges in defining nanomedicines, their
properties, the complexities of regulatory frameworks, and the imperative for standardized
characterization protocols., Polje nanotehnologije se nalazi na čelu naučne revolucije, gde se termin "nano" izdiže iznad pukog označavanja veličine, otvarajući vrata novim mogućnostima. U kontekstu razvoja lekova, izbor odgovarajućeg sistema za isporuku / nosača (koji odgovara određenoj aktivnoj supstanci) predstavlja ključnu odluku. U tom kontekstu, nanosistemi već određeno vreme predstavljaju inovativna rešenja. Iako farmaceutski nanosistemi nose ogroman potencijal, suočavaju se sa određenim izazovima u pogledu translacije sa prekliničkog na klinički nivo, što se ogleda u nedostatku odgovarajućih protokola za ispitivanje kvaliteta i bezbednosti i, shodno tome, nedefinisanom regulatornom okruženju. Od revolucionarnog odobrenja liposomalnog doksorubicina od strane Američke agencije za hranu i lekove 1995. godine, pa sve do danas, oko 80 nano formulacija (nanolekova) odobreno je za kliničku primenu. Odnedavno je intenzivnija pažnja usmerena ka nanoformulacijama baziranim na lipidima, što je delom posledica razvoja mRNK vakcina tokom pandemije COVID-19. Međutim, relativno skroman nastup nanolekova na tržištu (u poređenju sa obimnim istraživačkim naporima i finansijskim ulaganjima u ovu oblast) otvara važna pitanja. Ovaj rad pruža pregled izazova u definisanju nanolekova, njihovih svojstava, kompleksnosti regulatornih okvira i imperativa za stvaranje standardizovanih protokola karakterizacije.",
publisher = "Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "The Landscape of Nanomedicines: An Expert Perspective, "Pejzažni" prikaz nanolekova - ekspertska perspektiva",
volume = "73",
number = "5",
pages = "390-403",
doi = "10.5937/arhfarm73-46686"
}

Nikolić, I., Filipić, B., Marija Petrović, Jordan, O., Savić, S.,& Borchard, G.. (2023). The Landscape of Nanomedicines: An Expert Perspective. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije., 73(5), 390-403.
https://doi.org/10.5937/arhfarm73-46686

Nikolić I, Filipić B, Marija Petrović, Jordan O, Savić S, Borchard G. The Landscape of Nanomedicines: An Expert Perspective. in Arhiv za farmaciju. 2023;73(5):390-403.
doi:10.5937/arhfarm73-46686 .

Nikolić, Ines, Filipić, Brankica, Marija Petrović, Jordan, Olivier, Savić, Snežana, Borchard, Gerrit, "The Landscape of Nanomedicines: An Expert Perspective" in Arhiv za farmaciju, 73, no. 5 (2023):390-403,
https://doi.org/10.5937/arhfarm73-46686 . .

TY  - JOUR
AU  - Filipić, Brankica
AU  - Pantelić, Ivana
AU  - Nikolić, Ines
AU  - Majhen, Dragomira
AU  - Stojić-Vukanić, Zorica
AU  - Savić, Snežana
AU  - Krajišnik, Danina
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4960
AB  - Ever since the development of the first vaccine, vaccination has had the great impact on global health, leading to the decrease in the burden of numerous infectious diseases. However, there is a constant need to improve existing vaccines and develop new vaccination strategies and vaccine platforms that induce a broader immune response compared to traditional vaccines. Modern vaccines tend to rely on certain nanotechnology platforms but are still expected to be readily available and easy for large-scale manufacturing and to induce a durable immune response. In this review, we present an overview of the most promising nanoadjuvants and nanoparticulate delivery systems and discuss their benefits from tehchnological and immunological standpoints as well as their objective drawbacks and possible side effects. The presented nano alums, silica and clay nanoparticles, nanoemulsions, adenoviral-vectored systems, adeno-associated viral vectors, vesicular stomatitis viral vectors, lentiviral vectors, virus-like particles (including bacteriophage-based ones) and virosomes indicate that vaccine developers can now choose different adjuvants and/or delivery systems as per the requirement, specific to combatting different infectious diseases.
PB  - MDPI
T2  - Vaccines
T1  - Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines
VL  - 11
IS  - 7
DO  - 10.3390/vaccines11071172
ER  - 

@article{
author = "Filipić, Brankica and Pantelić, Ivana and Nikolić, Ines and Majhen, Dragomira and Stojić-Vukanić, Zorica and Savić, Snežana and Krajišnik, Danina",
year = "2023",
abstract = "Ever since the development of the first vaccine, vaccination has had the great impact on global health, leading to the decrease in the burden of numerous infectious diseases. However, there is a constant need to improve existing vaccines and develop new vaccination strategies and vaccine platforms that induce a broader immune response compared to traditional vaccines. Modern vaccines tend to rely on certain nanotechnology platforms but are still expected to be readily available and easy for large-scale manufacturing and to induce a durable immune response. In this review, we present an overview of the most promising nanoadjuvants and nanoparticulate delivery systems and discuss their benefits from tehchnological and immunological standpoints as well as their objective drawbacks and possible side effects. The presented nano alums, silica and clay nanoparticles, nanoemulsions, adenoviral-vectored systems, adeno-associated viral vectors, vesicular stomatitis viral vectors, lentiviral vectors, virus-like particles (including bacteriophage-based ones) and virosomes indicate that vaccine developers can now choose different adjuvants and/or delivery systems as per the requirement, specific to combatting different infectious diseases.",
publisher = "MDPI",
journal = "Vaccines",
title = "Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines",
volume = "11",
number = "7",
doi = "10.3390/vaccines11071172"
}

Filipić, B., Pantelić, I., Nikolić, I., Majhen, D., Stojić-Vukanić, Z., Savić, S.,& Krajišnik, D.. (2023). Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines. in Vaccines
MDPI., 11(7).
https://doi.org/10.3390/vaccines11071172

Filipić B, Pantelić I, Nikolić I, Majhen D, Stojić-Vukanić Z, Savić S, Krajišnik D. Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines. in Vaccines. 2023;11(7).
doi:10.3390/vaccines11071172 .

Filipić, Brankica, Pantelić, Ivana, Nikolić, Ines, Majhen, Dragomira, Stojić-Vukanić, Zorica, Savić, Snežana, Krajišnik, Danina, "Nanoparticle-Based Adjuvants and Delivery Systems for Modern Vaccines" in Vaccines, 11, no. 7 (2023),
https://doi.org/10.3390/vaccines11071172 . .

TY  - CONF
AU  - Filipić, Brankica
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5226
AB  - Human papilloma viruses (HPV) are small non-enveloped DNA viruses that posses
great affinity for epithelial tissue. So far, more than 200 genotypes of HPV have been
identified, of which around 40 types are associated with genital infections in man and
woman. HPV is the most sexually transmited virus in the world leading to the fact that
HPV infection is the major cause of cervical cancer. Besides, HPV is thought to be
responsible for more than 90% of anal cancer, 70% of vaginal and vulvar cancer, 70%
of oropharingeal cancer and 60% of penile cancer [1, 2]. HPV vaccinationn is the most
effective procedure in prevention of HPV-related cancers. Prophylactic 9-valent HPV
vaccine which targets high-risk HPV types is the most preferable one and is available
in many countries worlwide including Balkan region. The main goal of this presentation
is to improve awareness of great importance of HPV vaccination in target popullations.
PB  - Komora magistara farmacije Federacije Bosne i hercegovine
PB  - Farmaceutska komora Republike Srpske
PB  - Farmaceutsko društvo Republike Srpske
C3  - 5th Congress of Pharmacists of Bosnia and Herzegovina with international participation, Abstract book, „Competencies of pharmacists – from drug design to successful disease treatment“
T1  - About the HPV vaccine: how it works and who can get it
SP  - 35
EP  - 36
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5226
ER  - 

@conference{
author = "Filipić, Brankica",
year = "2023",
abstract = "Human papilloma viruses (HPV) are small non-enveloped DNA viruses that posses
great affinity for epithelial tissue. So far, more than 200 genotypes of HPV have been
identified, of which around 40 types are associated with genital infections in man and
woman. HPV is the most sexually transmited virus in the world leading to the fact that
HPV infection is the major cause of cervical cancer. Besides, HPV is thought to be
responsible for more than 90% of anal cancer, 70% of vaginal and vulvar cancer, 70%
of oropharingeal cancer and 60% of penile cancer [1, 2]. HPV vaccinationn is the most
effective procedure in prevention of HPV-related cancers. Prophylactic 9-valent HPV
vaccine which targets high-risk HPV types is the most preferable one and is available
in many countries worlwide including Balkan region. The main goal of this presentation
is to improve awareness of great importance of HPV vaccination in target popullations.",
publisher = "Komora magistara farmacije Federacije Bosne i hercegovine, Farmaceutska komora Republike Srpske, Farmaceutsko društvo Republike Srpske",
journal = "5th Congress of Pharmacists of Bosnia and Herzegovina with international participation, Abstract book, „Competencies of pharmacists – from drug design to successful disease treatment“",
title = "About the HPV vaccine: how it works and who can get it",
pages = "35-36",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5226"
}

Filipić, B.. (2023). About the HPV vaccine: how it works and who can get it. in 5th Congress of Pharmacists of Bosnia and Herzegovina with international participation, Abstract book, „Competencies of pharmacists – from drug design to successful disease treatment“
Komora magistara farmacije Federacije Bosne i hercegovine., 35-36.
https://hdl.handle.net/21.15107/rcub_farfar_5226

Filipić B. About the HPV vaccine: how it works and who can get it. in 5th Congress of Pharmacists of Bosnia and Herzegovina with international participation, Abstract book, „Competencies of pharmacists – from drug design to successful disease treatment“. 2023;:35-36.
https://hdl.handle.net/21.15107/rcub_farfar_5226 .

Filipić, Brankica, "About the HPV vaccine: how it works and who can get it" in 5th Congress of Pharmacists of Bosnia and Herzegovina with international participation, Abstract book, „Competencies of pharmacists – from drug design to successful disease treatment“ (2023):35-36,
https://hdl.handle.net/21.15107/rcub_farfar_5226 .

TY  - GEN
AU  - Rajković, Dragana
AU  - Filipić, Brankica
AU  - Tadić, Ivana
AU  - Rakić, Milan
AU  - Trunić, Marina
AU  - Letić, Bojana
AU  - Stojiljković, Dragana
AU  - Urošević, Jasna
AU  - Šipetić, Tatjana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5117
AB  - Uvod: Na osnovu podataka iz 2020, u Republici Srbiji je kod 1205 žena postavljena dijagnoza karcinoma grlića materice, dok su 643 žene preminule od ove bolesti. Karcinom grlića materice je peti po učestalosti karcinom kod žena u Srbiji i drugi po učestalosti karcinom kod žena između 15 i 44 godina starosti. ...
PB  - Farmaceutska komora Crne Gore
T2  - 4. kongres farmaceuta Crne Gore sa međunarodnim učešćem, 11-14. maj 2023 Budva, Bečići, Crna Gora
T1  - Jačanje uloge farmaceuta u promociji značaja HPV vakcinacije u Srbiji na nacionalnom i regionalnom nivou
SP  - 44
EP  - 44
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5117
ER  - 

@misc{
author = "Rajković, Dragana and Filipić, Brankica and Tadić, Ivana and Rakić, Milan and Trunić, Marina and Letić, Bojana and Stojiljković, Dragana and Urošević, Jasna and Šipetić, Tatjana",
year = "2023",
abstract = "Uvod: Na osnovu podataka iz 2020, u Republici Srbiji je kod 1205 žena postavljena dijagnoza karcinoma grlića materice, dok su 643 žene preminule od ove bolesti. Karcinom grlića materice je peti po učestalosti karcinom kod žena u Srbiji i drugi po učestalosti karcinom kod žena između 15 i 44 godina starosti. ...",
publisher = "Farmaceutska komora Crne Gore",
journal = "4. kongres farmaceuta Crne Gore sa međunarodnim učešćem, 11-14. maj 2023 Budva, Bečići, Crna Gora",
title = "Jačanje uloge farmaceuta u promociji značaja HPV vakcinacije u Srbiji na nacionalnom i regionalnom nivou",
pages = "44-44",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5117"
}

Rajković, D., Filipić, B., Tadić, I., Rakić, M., Trunić, M., Letić, B., Stojiljković, D., Urošević, J.,& Šipetić, T.. (2023). Jačanje uloge farmaceuta u promociji značaja HPV vakcinacije u Srbiji na nacionalnom i regionalnom nivou. in 4. kongres farmaceuta Crne Gore sa međunarodnim učešćem, 11-14. maj 2023 Budva, Bečići, Crna Gora
Farmaceutska komora Crne Gore., 44-44.
https://hdl.handle.net/21.15107/rcub_farfar_5117

Rajković D, Filipić B, Tadić I, Rakić M, Trunić M, Letić B, Stojiljković D, Urošević J, Šipetić T. Jačanje uloge farmaceuta u promociji značaja HPV vakcinacije u Srbiji na nacionalnom i regionalnom nivou. in 4. kongres farmaceuta Crne Gore sa međunarodnim učešćem, 11-14. maj 2023 Budva, Bečići, Crna Gora. 2023;:44-44.
https://hdl.handle.net/21.15107/rcub_farfar_5117 .

Rajković, Dragana, Filipić, Brankica, Tadić, Ivana, Rakić, Milan, Trunić, Marina, Letić, Bojana, Stojiljković, Dragana, Urošević, Jasna, Šipetić, Tatjana, "Jačanje uloge farmaceuta u promociji značaja HPV vakcinacije u Srbiji na nacionalnom i regionalnom nivou" in 4. kongres farmaceuta Crne Gore sa međunarodnim učešćem, 11-14. maj 2023 Budva, Bečići, Crna Gora (2023):44-44,
https://hdl.handle.net/21.15107/rcub_farfar_5117 .

TY  - JOUR
AU  - Novović, Katarina
AU  - Kuzmanović Nedeljković, Snežana
AU  - Poledica, Mirjana
AU  - Nikolić, Gordana
AU  - Grujić, Bojana
AU  - Jovčić, Branko
AU  - Kojić, Milan
AU  - Filipić, Brankica
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4471
AB  - Since the WHO declared the COVID-19 pandemic in March 2020, the disease has spread rapidly leading to overload of the health system and many of the patients infected with SARS-CoV-2 needed to be admitted to the intensive care unit (ICU). Around 10% of patients with the severe manifestation of COVID-19 need noninvasive or invasive mechanical ventilation, which represent a risk factor for Acinetobacter baumannii superinfection. The 64 A. baumannii isolates were recovered from COVID-19 patients admitted to ICU at General Hospital “Dr Laza K. Lazarević” Šabac, Serbia, during the period from December 2020 to February 2021. All patients required mechanical ventilation and mortality rate was 100%. The goal of this study was to evaluate antibiotic resistance profiles and virulence potential of A. baumannii isolates recovered from patients with severe form of COVID-19 who had a need for mechanical ventilation. All tested A. baumannii isolates (n = 64) were sensitive to colistin, while resistant to meropenem, imipenem, gentamicin, tobramycin, and levofloxacin according to the broth microdilution method and MDR phenotype was confirmed. In all tested isolates, representatives of international clone 2 (IC2) classified by multiplex PCR for clonal lineage identification, blaAmpC, blaOXA-51, and blaOXA-23 genes were present, as well as ISAba1 insertion sequence upstream of blaOXA-23. Clonal distribution of one dominant strain was found, but individual strains showed phenotypic differences in the level of antibiotic resistance, biofilm formation, and binding to mucin and motility. According to PFGE, four isolates were sequenced and antibiotic resistance genes as well as virulence factors genes were analyzed in these genomes. The results of this study represent the first report on virulence potential of MDR A. baumannii from hospital in Serbia.
PB  - Frontiers Media S.A.
T2  - Frontiers in Microbiology
T1  - Virulence potential of multidrug-resistant Acinetobacter baumannii isolates from COVID-19 patients on mechanical ventilation: The first report from Serbia
VL  - 14
DO  - 10.3389/fmicb.2023.1094184
ER  - 

@article{
author = "Novović, Katarina and Kuzmanović Nedeljković, Snežana and Poledica, Mirjana and Nikolić, Gordana and Grujić, Bojana and Jovčić, Branko and Kojić, Milan and Filipić, Brankica",
year = "2023",
abstract = "Since the WHO declared the COVID-19 pandemic in March 2020, the disease has spread rapidly leading to overload of the health system and many of the patients infected with SARS-CoV-2 needed to be admitted to the intensive care unit (ICU). Around 10% of patients with the severe manifestation of COVID-19 need noninvasive or invasive mechanical ventilation, which represent a risk factor for Acinetobacter baumannii superinfection. The 64 A. baumannii isolates were recovered from COVID-19 patients admitted to ICU at General Hospital “Dr Laza K. Lazarević” Šabac, Serbia, during the period from December 2020 to February 2021. All patients required mechanical ventilation and mortality rate was 100%. The goal of this study was to evaluate antibiotic resistance profiles and virulence potential of A. baumannii isolates recovered from patients with severe form of COVID-19 who had a need for mechanical ventilation. All tested A. baumannii isolates (n = 64) were sensitive to colistin, while resistant to meropenem, imipenem, gentamicin, tobramycin, and levofloxacin according to the broth microdilution method and MDR phenotype was confirmed. In all tested isolates, representatives of international clone 2 (IC2) classified by multiplex PCR for clonal lineage identification, blaAmpC, blaOXA-51, and blaOXA-23 genes were present, as well as ISAba1 insertion sequence upstream of blaOXA-23. Clonal distribution of one dominant strain was found, but individual strains showed phenotypic differences in the level of antibiotic resistance, biofilm formation, and binding to mucin and motility. According to PFGE, four isolates were sequenced and antibiotic resistance genes as well as virulence factors genes were analyzed in these genomes. The results of this study represent the first report on virulence potential of MDR A. baumannii from hospital in Serbia.",
publisher = "Frontiers Media S.A.",
journal = "Frontiers in Microbiology",
title = "Virulence potential of multidrug-resistant Acinetobacter baumannii isolates from COVID-19 patients on mechanical ventilation: The first report from Serbia",
volume = "14",
doi = "10.3389/fmicb.2023.1094184"
}

Novović, K., Kuzmanović Nedeljković, S., Poledica, M., Nikolić, G., Grujić, B., Jovčić, B., Kojić, M.,& Filipić, B.. (2023). Virulence potential of multidrug-resistant Acinetobacter baumannii isolates from COVID-19 patients on mechanical ventilation: The first report from Serbia. in Frontiers in Microbiology
Frontiers Media S.A.., 14.
https://doi.org/10.3389/fmicb.2023.1094184

Novović K, Kuzmanović Nedeljković S, Poledica M, Nikolić G, Grujić B, Jovčić B, Kojić M, Filipić B. Virulence potential of multidrug-resistant Acinetobacter baumannii isolates from COVID-19 patients on mechanical ventilation: The first report from Serbia. in Frontiers in Microbiology. 2023;14.
doi:10.3389/fmicb.2023.1094184 .

Novović, Katarina, Kuzmanović Nedeljković, Snežana, Poledica, Mirjana, Nikolić, Gordana, Grujić, Bojana, Jovčić, Branko, Kojić, Milan, Filipić, Brankica, "Virulence potential of multidrug-resistant Acinetobacter baumannii isolates from COVID-19 patients on mechanical ventilation: The first report from Serbia" in Frontiers in Microbiology, 14 (2023),
https://doi.org/10.3389/fmicb.2023.1094184 . .

TY  - CONF
AU  - Filipić, Brankica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5585
AB  - Koronavirusi pripadaju RNK virusima, a naziv potiče od latinske reči “corona” usled slič-
nosti sa vencem (koronom) sunčevih zraka. Sve do početka 21. veka, koronavirusi su povezi-
vani sa sezonskim prehladama i nisu bili prepoznati kao značajni humani patogeni.
Međutim, 2002. godine u Kini je identifikovan uzročnik teškog akutnog respiratornog sin-
droma – SARS (engl. Severe acute respiratory syndrome), pri čemu su zabeleženi smrtni isho-
di, a virus je označen kao SARS-CoV. Deset godina kasnije, 2012. godine, u Saudijskoj Arabiji
identifikovan je MERS-CoV (engl. Middle East respiratory syndrome Coronavirus), a krajem
2019. godine i novi koronavirus koji je kasnije označen kao SARS-CoV-2 usled sličnosti sa
SARS-CoV. Broj umrlih usled infekcije SARS-CoV-2 i razvoja bolesti COVID-19 (engl. coronavi-
rus disease 2019) procenjuje se do sada na oko 6 miliona ljudi globalno.
Usled brzog širenja SARS-CoV-2, Svetska Zdravstvena Organizacija objavila je 11. marta
2020. pandemiju, koja je još uvek na snazi. Pandemija je dovela do brzog odgovora na COVID-19
što je za posledicu imalo velika finansijska ulaganja u razvoj bolničkih kapaciteta, novih tera-
pijskih opcija, a posebno na razvoj vakcina protiv COVID-19. Međutim, paralelno sa razvojem i
primenom vakcina došlo je do mutacija u genomu SARS-CoV-2 i pojave novih varijanti virusa što
je posledično dovelo do manje efikasnosti vakcina i dostupnih terapijskih opcija.
U okviru izlaganja dat je uporedni pregled karakteristika virusa SARS-CoV, MERS-CoV i
SARS-CoV-2. Pažnja koju su privukli koronavirusi 21. veka i iskustva i znanja stečena njiho-
vom pojavom, omogući će bolji odgovor na potencijalno nove koronaviruse, kao i bolji odgo-
vor na epidemije ili pandemije uzrokovane drugim patogenima.
PB  - Udruženje farmaceuta Beograd
C3  - Simpozijum "Covid-19 infekcija-dijagnostički i prognostički biohemijski parametri", Program i zbornik sažetaka, 18.03.2022, Beograd
T1  - Koronavirusi i 21. vek
SP  - 9
EP  - 9
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5585
ER  - 

@conference{
author = "Filipić, Brankica",
year = "2022",
abstract = "Koronavirusi pripadaju RNK virusima, a naziv potiče od latinske reči “corona” usled slič-
nosti sa vencem (koronom) sunčevih zraka. Sve do početka 21. veka, koronavirusi su povezi-
vani sa sezonskim prehladama i nisu bili prepoznati kao značajni humani patogeni.
Međutim, 2002. godine u Kini je identifikovan uzročnik teškog akutnog respiratornog sin-
droma – SARS (engl. Severe acute respiratory syndrome), pri čemu su zabeleženi smrtni isho-
di, a virus je označen kao SARS-CoV. Deset godina kasnije, 2012. godine, u Saudijskoj Arabiji
identifikovan je MERS-CoV (engl. Middle East respiratory syndrome Coronavirus), a krajem
2019. godine i novi koronavirus koji je kasnije označen kao SARS-CoV-2 usled sličnosti sa
SARS-CoV. Broj umrlih usled infekcije SARS-CoV-2 i razvoja bolesti COVID-19 (engl. coronavi-
rus disease 2019) procenjuje se do sada na oko 6 miliona ljudi globalno.
Usled brzog širenja SARS-CoV-2, Svetska Zdravstvena Organizacija objavila je 11. marta
2020. pandemiju, koja je još uvek na snazi. Pandemija je dovela do brzog odgovora na COVID-19
što je za posledicu imalo velika finansijska ulaganja u razvoj bolničkih kapaciteta, novih tera-
pijskih opcija, a posebno na razvoj vakcina protiv COVID-19. Međutim, paralelno sa razvojem i
primenom vakcina došlo je do mutacija u genomu SARS-CoV-2 i pojave novih varijanti virusa što
je posledično dovelo do manje efikasnosti vakcina i dostupnih terapijskih opcija.
U okviru izlaganja dat je uporedni pregled karakteristika virusa SARS-CoV, MERS-CoV i
SARS-CoV-2. Pažnja koju su privukli koronavirusi 21. veka i iskustva i znanja stečena njiho-
vom pojavom, omogući će bolji odgovor na potencijalno nove koronaviruse, kao i bolji odgo-
vor na epidemije ili pandemije uzrokovane drugim patogenima.",
publisher = "Udruženje farmaceuta Beograd",
journal = "Simpozijum "Covid-19 infekcija-dijagnostički i prognostički biohemijski parametri", Program i zbornik sažetaka, 18.03.2022, Beograd",
title = "Koronavirusi i 21. vek",
pages = "9-9",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5585"
}

Filipić, B.. (2022). Koronavirusi i 21. vek. in Simpozijum "Covid-19 infekcija-dijagnostički i prognostički biohemijski parametri", Program i zbornik sažetaka, 18.03.2022, Beograd
Udruženje farmaceuta Beograd., 9-9.
https://hdl.handle.net/21.15107/rcub_farfar_5585

Filipić B. Koronavirusi i 21. vek. in Simpozijum "Covid-19 infekcija-dijagnostički i prognostički biohemijski parametri", Program i zbornik sažetaka, 18.03.2022, Beograd. 2022;:9-9.
https://hdl.handle.net/21.15107/rcub_farfar_5585 .

Filipić, Brankica, "Koronavirusi i 21. vek" in Simpozijum "Covid-19 infekcija-dijagnostički i prognostički biohemijski parametri", Program i zbornik sažetaka, 18.03.2022, Beograd (2022):9-9,
https://hdl.handle.net/21.15107/rcub_farfar_5585 .

TY  - CONF
AU  - Filipić, Brankica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5227
AB  - Pandemija uzrokovana SARS-CoV-2 dovela je do sada do oko 6 miliona smrtnih
ishoda globalno. Usled hitnosti da se pandemija zaustavi, uloženi su veliki napori u razvoj
COVID-19 vakcina, s obzirom da vakcinacija predstavlja jedno od najefikasnijih oruđa za spre-
čavanje širenja infektivnih bolesti. Cilj ovog rada je da se napravi pregled COVID-19 vakcina
dostupnih u našoj zemlji.
PB  - Udruženje farmaceuta Beograd
C3  - Simpozijum "Covid-19 infekcija-dijagnostički i prognostički biohemijski parametri", Program i zbornik sažetaka, 18.03.2022, Beograd
T1  - COVID-19 vakcine dostupne u Republici Srbiji
SP  - 23
EP  - 23
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5227
ER  - 

@conference{
author = "Filipić, Brankica",
year = "2022",
abstract = "Pandemija uzrokovana SARS-CoV-2 dovela je do sada do oko 6 miliona smrtnih
ishoda globalno. Usled hitnosti da se pandemija zaustavi, uloženi su veliki napori u razvoj
COVID-19 vakcina, s obzirom da vakcinacija predstavlja jedno od najefikasnijih oruđa za spre-
čavanje širenja infektivnih bolesti. Cilj ovog rada je da se napravi pregled COVID-19 vakcina
dostupnih u našoj zemlji.",
publisher = "Udruženje farmaceuta Beograd",
journal = "Simpozijum "Covid-19 infekcija-dijagnostički i prognostički biohemijski parametri", Program i zbornik sažetaka, 18.03.2022, Beograd",
title = "COVID-19 vakcine dostupne u Republici Srbiji",
pages = "23-23",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5227"
}

Filipić, B.. (2022). COVID-19 vakcine dostupne u Republici Srbiji. in Simpozijum "Covid-19 infekcija-dijagnostički i prognostički biohemijski parametri", Program i zbornik sažetaka, 18.03.2022, Beograd
Udruženje farmaceuta Beograd., 23-23.
https://hdl.handle.net/21.15107/rcub_farfar_5227

Filipić B. COVID-19 vakcine dostupne u Republici Srbiji. in Simpozijum "Covid-19 infekcija-dijagnostički i prognostički biohemijski parametri", Program i zbornik sažetaka, 18.03.2022, Beograd. 2022;:23-23.
https://hdl.handle.net/21.15107/rcub_farfar_5227 .

Filipić, Brankica, "COVID-19 vakcine dostupne u Republici Srbiji" in Simpozijum "Covid-19 infekcija-dijagnostički i prognostički biohemijski parametri", Program i zbornik sažetaka, 18.03.2022, Beograd (2022):23-23,
https://hdl.handle.net/21.15107/rcub_farfar_5227 .

TY  - CONF
AU  - Ušjak, Dušan
AU  - Novović, Katarina
AU  - Filipić, Brankica
AU  - Kojić, Milan
AU  - Filipović, Nenad
AU  - Stevanović, Magdalena M.
AU  - Arsenović-Ranin, Nevena
AU  - Milenković, Marina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5133
AB  - Colistin is used as a “last resort” drug in the treatment
of carbapenem-resistant Acinetobacter baumannii
infections. Though not the most convenient option due to
the serious side effects, this antibiotic can be very efficient
if administered properly (Garnacho-Montero and Timsit,
2019). However, for several years now, we are witnessing
a steady emergence of colistin-resistant (ColR) strains, with
the constant threat of a sudden burst worldwide (Nowak et
al., 2017). Having in mind that these strains are usually
non-susceptible to any of the existing treatments, i.e.
pandrug-resistant (PDR), the development of new
therapeutic strategies is desperately needed.
In the present study, we showed that colistin
susceptibility of ColR A. baumannii strains can be fully
restored in the presence of very low amounts of selenium
nanoparticles (SeNPs). To demonstrate potent synergistic
interactions between colistin and SeNPs, we performed
checkerboard and time-kill analyses.
PB  - Macedonian Pharmaceutical Association
C3  - Macedonian Pharmaceutical Bulletin
T1  - Selenium nanoparticles render pandrug-resistant Acinetobacter  baumannii susceptible to colistin
VL  - 68
IS  - Suppl. 1
SP  - 295
EP  - 296
DO  - 10.33320/maced.pharm.bull.2022.68.03.142
ER  - 

@conference{
author = "Ušjak, Dušan and Novović, Katarina and Filipić, Brankica and Kojić, Milan and Filipović, Nenad and Stevanović, Magdalena M. and Arsenović-Ranin, Nevena and Milenković, Marina",
year = "2022",
abstract = "Colistin is used as a “last resort” drug in the treatment
of carbapenem-resistant Acinetobacter baumannii
infections. Though not the most convenient option due to
the serious side effects, this antibiotic can be very efficient
if administered properly (Garnacho-Montero and Timsit,
2019). However, for several years now, we are witnessing
a steady emergence of colistin-resistant (ColR) strains, with
the constant threat of a sudden burst worldwide (Nowak et
al., 2017). Having in mind that these strains are usually
non-susceptible to any of the existing treatments, i.e.
pandrug-resistant (PDR), the development of new
therapeutic strategies is desperately needed.
In the present study, we showed that colistin
susceptibility of ColR A. baumannii strains can be fully
restored in the presence of very low amounts of selenium
nanoparticles (SeNPs). To demonstrate potent synergistic
interactions between colistin and SeNPs, we performed
checkerboard and time-kill analyses.",
publisher = "Macedonian Pharmaceutical Association",
journal = "Macedonian Pharmaceutical Bulletin",
title = "Selenium nanoparticles render pandrug-resistant Acinetobacter  baumannii susceptible to colistin",
volume = "68",
number = "Suppl. 1",
pages = "295-296",
doi = "10.33320/maced.pharm.bull.2022.68.03.142"
}

Ušjak, D., Novović, K., Filipić, B., Kojić, M., Filipović, N., Stevanović, M. M., Arsenović-Ranin, N.,& Milenković, M.. (2022). Selenium nanoparticles render pandrug-resistant Acinetobacter  baumannii susceptible to colistin. in Macedonian Pharmaceutical Bulletin
Macedonian Pharmaceutical Association., 68(Suppl. 1), 295-296.
https://doi.org/10.33320/maced.pharm.bull.2022.68.03.142

Ušjak D, Novović K, Filipić B, Kojić M, Filipović N, Stevanović MM, Arsenović-Ranin N, Milenković M. Selenium nanoparticles render pandrug-resistant Acinetobacter  baumannii susceptible to colistin. in Macedonian Pharmaceutical Bulletin. 2022;68(Suppl. 1):295-296.
doi:10.33320/maced.pharm.bull.2022.68.03.142 .

Ušjak, Dušan, Novović, Katarina, Filipić, Brankica, Kojić, Milan, Filipović, Nenad, Stevanović, Magdalena M., Arsenović-Ranin, Nevena, Milenković, Marina, "Selenium nanoparticles render pandrug-resistant Acinetobacter  baumannii susceptible to colistin" in Macedonian Pharmaceutical Bulletin, 68, no. Suppl. 1 (2022):295-296,
https://doi.org/10.33320/maced.pharm.bull.2022.68.03.142 . .

TY  - JOUR
AU  - Filipić, Brankica
AU  - Malešević, Milka
AU  - Vasiljević, Zorica
AU  - Novović, Katarina
AU  - Kojić, Milan
AU  - Jovčić, Branko
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4370
AB  - Trimethoprim-sulfamethoxazole (SXT) is the preferable treatment option of the infections caused by Achromobacter spp. Our study aimed to analyze the SXT resistance of 98 Achromobacter spp. isolates from pediatric patients, among which 33 isolates were SXT-resistant. The presence of intI1 was screened by PCR and genome sequence analyses. The intI1 gene was detected in 10 of SXT-resistant isolates that had shorter intI1 PCR fragments named intI1S. Structural changes in intI1S were confirmed by genome sequencing and analyses which revealed 86 amino acids deletion in IntI1S protein compared to canonical IntI1 protein. All IntI1S isolates were of non-CF origin. Pan-genome analysis of intI1S bearing A. xylosoxidans isolates comprised 9052 genes, with the core genome consisting of 5455 protein-coding genes. Results in this study indicate that IntI1S isolates were derived from clinical settings and that cystic fibrosis (CF) patients were potential reservoirs for healthcare-associated infections that occurred in non-CF patients.
PB  - Springer Science and Business Media B.V.
T2  - Folia Microbiologica
T1  - Comparative genomics of trimethoprim-sulfamethoxazole-resistant Achromobacter xylosoxidans clinical isolates from Serbia reveals shortened variant of class 1 integron integrase gene
VL  - n/d
DO  - 10.1007/s12223-022-01026-8
ER  - 

@article{
author = "Filipić, Brankica and Malešević, Milka and Vasiljević, Zorica and Novović, Katarina and Kojić, Milan and Jovčić, Branko",
year = "2022",
abstract = "Trimethoprim-sulfamethoxazole (SXT) is the preferable treatment option of the infections caused by Achromobacter spp. Our study aimed to analyze the SXT resistance of 98 Achromobacter spp. isolates from pediatric patients, among which 33 isolates were SXT-resistant. The presence of intI1 was screened by PCR and genome sequence analyses. The intI1 gene was detected in 10 of SXT-resistant isolates that had shorter intI1 PCR fragments named intI1S. Structural changes in intI1S were confirmed by genome sequencing and analyses which revealed 86 amino acids deletion in IntI1S protein compared to canonical IntI1 protein. All IntI1S isolates were of non-CF origin. Pan-genome analysis of intI1S bearing A. xylosoxidans isolates comprised 9052 genes, with the core genome consisting of 5455 protein-coding genes. Results in this study indicate that IntI1S isolates were derived from clinical settings and that cystic fibrosis (CF) patients were potential reservoirs for healthcare-associated infections that occurred in non-CF patients.",
publisher = "Springer Science and Business Media B.V.",
journal = "Folia Microbiologica",
title = "Comparative genomics of trimethoprim-sulfamethoxazole-resistant Achromobacter xylosoxidans clinical isolates from Serbia reveals shortened variant of class 1 integron integrase gene",
volume = "n/d",
doi = "10.1007/s12223-022-01026-8"
}

Filipić, B., Malešević, M., Vasiljević, Z., Novović, K., Kojić, M.,& Jovčić, B.. (2022). Comparative genomics of trimethoprim-sulfamethoxazole-resistant Achromobacter xylosoxidans clinical isolates from Serbia reveals shortened variant of class 1 integron integrase gene. in Folia Microbiologica
Springer Science and Business Media B.V.., n/d.
https://doi.org/10.1007/s12223-022-01026-8

Filipić B, Malešević M, Vasiljević Z, Novović K, Kojić M, Jovčić B. Comparative genomics of trimethoprim-sulfamethoxazole-resistant Achromobacter xylosoxidans clinical isolates from Serbia reveals shortened variant of class 1 integron integrase gene. in Folia Microbiologica. 2022;n/d.
doi:10.1007/s12223-022-01026-8 .

Filipić, Brankica, Malešević, Milka, Vasiljević, Zorica, Novović, Katarina, Kojić, Milan, Jovčić, Branko, "Comparative genomics of trimethoprim-sulfamethoxazole-resistant Achromobacter xylosoxidans clinical isolates from Serbia reveals shortened variant of class 1 integron integrase gene" in Folia Microbiologica, n/d (2022),
https://doi.org/10.1007/s12223-022-01026-8 . .

TY  - JOUR
AU  - Ušjak, Dušan
AU  - Novović, Katarina
AU  - Filipić, Brankica
AU  - Kojić, Milan
AU  - Filipović, Nenad
AU  - Stevanović, Magdalena
AU  - Milenković, Marina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4177
AB  - Aims: To investigate the synergistic activity of colistin and selenium nanoparticles (SeNPs) against pandrug-resistant (PDR) Ac. baumannii. Methods and Results: Chequerboard and time-kill assays were employed to ex- plore the potential synergistic interactions between colistin and SeNPs against Ac. baumannii isolates (8), previously determined as colistin-resistant (MIC range 16– 256 μg ml−1 ). Also, whole-genome sequencing (WGS) and gene expression analyses were used to elucidate the mechanisms of colistin resistance. Exceptionally strong synergistic activity (FICI range 0.004–0.035) of colistin and SeNPs against colistin- resistant isolates was revealed. Colistin (0.5 or 1 μg ml −1 ) used in combination with SeNPs (0.5 μg ml−1 ) was able to reduce initial inoculum during the first 4 h of incuba- tion, in contrast to colistin (0.5, 1 or 2 μg ml−1 ) alone. Conclusions: These findings propose colistin/SeNPs combination as a new option to fight PDR Ac. baumannii, the therapeutic possibilities of which should be proved in future in vivo studies. Significance and Impact of Study: Here we present the first evidence of synergy between colistin and selenium compounds against bacteria in general. Also, WGS and gene expression analyses provide some new insights into Ac. baumannii colistin resistance mechanisms.
PB  - John Wiley and Sons Inc
T2  - Journal of Applied Microbiology
T1  - In vitro colistin susceptibility of pandrug-resistant Ac. baumannii is restored in the presence of selenium nanoparticles
VL  - 133
IS  - 3
SP  - 1197
SP  - 1197
EP  - 1206
DO  - 10.1111/jam.15638
ER  - 

@article{
author = "Ušjak, Dušan and Novović, Katarina and Filipić, Brankica and Kojić, Milan and Filipović, Nenad and Stevanović, Magdalena and Milenković, Marina",
year = "2022",
abstract = "Aims: To investigate the synergistic activity of colistin and selenium nanoparticles (SeNPs) against pandrug-resistant (PDR) Ac. baumannii. Methods and Results: Chequerboard and time-kill assays were employed to ex- plore the potential synergistic interactions between colistin and SeNPs against Ac. baumannii isolates (8), previously determined as colistin-resistant (MIC range 16– 256 μg ml−1 ). Also, whole-genome sequencing (WGS) and gene expression analyses were used to elucidate the mechanisms of colistin resistance. Exceptionally strong synergistic activity (FICI range 0.004–0.035) of colistin and SeNPs against colistin- resistant isolates was revealed. Colistin (0.5 or 1 μg ml −1 ) used in combination with SeNPs (0.5 μg ml−1 ) was able to reduce initial inoculum during the first 4 h of incuba- tion, in contrast to colistin (0.5, 1 or 2 μg ml−1 ) alone. Conclusions: These findings propose colistin/SeNPs combination as a new option to fight PDR Ac. baumannii, the therapeutic possibilities of which should be proved in future in vivo studies. Significance and Impact of Study: Here we present the first evidence of synergy between colistin and selenium compounds against bacteria in general. Also, WGS and gene expression analyses provide some new insights into Ac. baumannii colistin resistance mechanisms.",
publisher = "John Wiley and Sons Inc",
journal = "Journal of Applied Microbiology",
title = "In vitro colistin susceptibility of pandrug-resistant Ac. baumannii is restored in the presence of selenium nanoparticles",
volume = "133",
number = "3",
pages = "1197-1197-1206",
doi = "10.1111/jam.15638"
}

Ušjak, D., Novović, K., Filipić, B., Kojić, M., Filipović, N., Stevanović, M.,& Milenković, M.. (2022). In vitro colistin susceptibility of pandrug-resistant Ac. baumannii is restored in the presence of selenium nanoparticles. in Journal of Applied Microbiology
John Wiley and Sons Inc., 133(3), 1197-1206.
https://doi.org/10.1111/jam.15638

Ušjak D, Novović K, Filipić B, Kojić M, Filipović N, Stevanović M, Milenković M. In vitro colistin susceptibility of pandrug-resistant Ac. baumannii is restored in the presence of selenium nanoparticles. in Journal of Applied Microbiology. 2022;133(3):1197-1206.
doi:10.1111/jam.15638 .

Ušjak, Dušan, Novović, Katarina, Filipić, Brankica, Kojić, Milan, Filipović, Nenad, Stevanović, Magdalena, Milenković, Marina, "In vitro colistin susceptibility of pandrug-resistant Ac. baumannii is restored in the presence of selenium nanoparticles" in Journal of Applied Microbiology, 133, no. 3 (2022):1197-1206,
https://doi.org/10.1111/jam.15638 . .

TY  - CONF
AU  - Kabić, Jovana
AU  - Luković, Bojana
AU  - Jovčić, Branko
AU  - Filipić, Brankica
AU  - Kekić, Dušan
AU  - Jovičević, Miloš
AU  - Ranin, Lazar
AU  - Opavski, Nataša
AU  - Dimkić, Ivica
AU  - Gajić, Ina
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5139
PB  - ESCMID
C3  - 32nd European Congress of Clinical Microbiology and Infectious Diseases, 23-26 April 2022 Lisabon - Final Programme
T1  - A core genome multilocus sequence typing of Acinetobacter baumannii isolated from pre-COVID-19 and COVID-19 period
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5139
ER  - 

@conference{
author = "Kabić, Jovana and Luković, Bojana and Jovčić, Branko and Filipić, Brankica and Kekić, Dušan and Jovičević, Miloš and Ranin, Lazar and Opavski, Nataša and Dimkić, Ivica and Gajić, Ina",
year = "2022",
publisher = "ESCMID",
journal = "32nd European Congress of Clinical Microbiology and Infectious Diseases, 23-26 April 2022 Lisabon - Final Programme",
title = "A core genome multilocus sequence typing of Acinetobacter baumannii isolated from pre-COVID-19 and COVID-19 period",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5139"
}

Kabić, J., Luković, B., Jovčić, B., Filipić, B., Kekić, D., Jovičević, M., Ranin, L., Opavski, N., Dimkić, I.,& Gajić, I.. (2022). A core genome multilocus sequence typing of Acinetobacter baumannii isolated from pre-COVID-19 and COVID-19 period. in 32nd European Congress of Clinical Microbiology and Infectious Diseases, 23-26 April 2022 Lisabon - Final Programme
ESCMID..
https://hdl.handle.net/21.15107/rcub_farfar_5139

Kabić J, Luković B, Jovčić B, Filipić B, Kekić D, Jovičević M, Ranin L, Opavski N, Dimkić I, Gajić I. A core genome multilocus sequence typing of Acinetobacter baumannii isolated from pre-COVID-19 and COVID-19 period. in 32nd European Congress of Clinical Microbiology and Infectious Diseases, 23-26 April 2022 Lisabon - Final Programme. 2022;.
https://hdl.handle.net/21.15107/rcub_farfar_5139 .

Kabić, Jovana, Luković, Bojana, Jovčić, Branko, Filipić, Brankica, Kekić, Dušan, Jovičević, Miloš, Ranin, Lazar, Opavski, Nataša, Dimkić, Ivica, Gajić, Ina, "A core genome multilocus sequence typing of Acinetobacter baumannii isolated from pre-COVID-19 and COVID-19 period" in 32nd European Congress of Clinical Microbiology and Infectious Diseases, 23-26 April 2022 Lisabon - Final Programme (2022),
https://hdl.handle.net/21.15107/rcub_farfar_5139 .

TY  - CONF
AU  - Filipić, Brankica
AU  - Novović, Katarina
AU  - Kuzmanović Nedeljković, Snežana
AU  - Jovčić, Branko
AU  - Kojić, Milan
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5118
AB  - BACKGROUND
From the start of COVID-19 pandemic, many patients suffering severe clinical presentation of COVID-19 and 
acute respiratory failure have been administered to intensive care units (ICUs). Need for noninvasive or invasive 
mechanical ventilation represents a high-risk factor for these patients to develop Acinetobacter baumannii 
superinfection.
OBJECTIVES
The main goal of this study was to examine virulence potential of A. baumannii isolates recovered from 
COVID-19 patients admitted to ICU as well as to compare differences in virulence among isolates originated 
from male and female patients or from different sample types.
METHODS
64 A. baumannii isolates were recovered from COVID-19 patients from December 2020 to February 2021. 
The isolates were originated from different sample types: blood, tip of the central venous catheter, tracheal 
aspirate, tip of the aspirator and sputum. Genetic relatedness of ApaI digested A. baumannii isolates, 
was determined by pulsed-field gel electrophoresis (PFGE). Affinity to mucin binding was tested using in vitro 
model and isolates were examined for two types of motilities: swarming and twitching.
PB  - Federation of European Microbiological Societies
PB  - Serbian Society for Microbiology
C3  - FEMS Conference on Microbiology in association with Serbian Society of Microbiology, 30 June - 2 July 2022, Serbia - electronic abstract book
T1  - Assesing virulence potential of Acinetobacter baumannii isolates recovered from COVID-19 patients
SP  - 96
EP  - 96
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5118
ER  - 

@conference{
author = "Filipić, Brankica and Novović, Katarina and Kuzmanović Nedeljković, Snežana and Jovčić, Branko and Kojić, Milan",
year = "2022",
abstract = "BACKGROUND
From the start of COVID-19 pandemic, many patients suffering severe clinical presentation of COVID-19 and 
acute respiratory failure have been administered to intensive care units (ICUs). Need for noninvasive or invasive 
mechanical ventilation represents a high-risk factor for these patients to develop Acinetobacter baumannii 
superinfection.
OBJECTIVES
The main goal of this study was to examine virulence potential of A. baumannii isolates recovered from 
COVID-19 patients admitted to ICU as well as to compare differences in virulence among isolates originated 
from male and female patients or from different sample types.
METHODS
64 A. baumannii isolates were recovered from COVID-19 patients from December 2020 to February 2021. 
The isolates were originated from different sample types: blood, tip of the central venous catheter, tracheal 
aspirate, tip of the aspirator and sputum. Genetic relatedness of ApaI digested A. baumannii isolates, 
was determined by pulsed-field gel electrophoresis (PFGE). Affinity to mucin binding was tested using in vitro 
model and isolates were examined for two types of motilities: swarming and twitching.",
publisher = "Federation of European Microbiological Societies, Serbian Society for Microbiology",
journal = "FEMS Conference on Microbiology in association with Serbian Society of Microbiology, 30 June - 2 July 2022, Serbia - electronic abstract book",
title = "Assesing virulence potential of Acinetobacter baumannii isolates recovered from COVID-19 patients",
pages = "96-96",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5118"
}

Filipić, B., Novović, K., Kuzmanović Nedeljković, S., Jovčić, B.,& Kojić, M.. (2022). Assesing virulence potential of Acinetobacter baumannii isolates recovered from COVID-19 patients. in FEMS Conference on Microbiology in association with Serbian Society of Microbiology, 30 June - 2 July 2022, Serbia - electronic abstract book
Federation of European Microbiological Societies., 96-96.
https://hdl.handle.net/21.15107/rcub_farfar_5118

Filipić B, Novović K, Kuzmanović Nedeljković S, Jovčić B, Kojić M. Assesing virulence potential of Acinetobacter baumannii isolates recovered from COVID-19 patients. in FEMS Conference on Microbiology in association with Serbian Society of Microbiology, 30 June - 2 July 2022, Serbia - electronic abstract book. 2022;:96-96.
https://hdl.handle.net/21.15107/rcub_farfar_5118 .

Filipić, Brankica, Novović, Katarina, Kuzmanović Nedeljković, Snežana, Jovčić, Branko, Kojić, Milan, "Assesing virulence potential of Acinetobacter baumannii isolates recovered from COVID-19 patients" in FEMS Conference on Microbiology in association with Serbian Society of Microbiology, 30 June - 2 July 2022, Serbia - electronic abstract book (2022):96-96,
https://hdl.handle.net/21.15107/rcub_farfar_5118 .

TY  - CONF
AU  - Kuzmanović Nedeljković, Snežana
AU  - Ćujić Nikolić, Nada
AU  - Bigović, Dubravka
AU  - Petrović, Predrag
AU  - Pljevljakušić, Dejan
AU  - Šavikin, Katarina
AU  - Filipić, Brankica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5120
AB  - Among plant natural products, Oregano and Thyme essential oils (EOs) are well-known for 
their antimicrobial and antioxidant activity. The biological activities of EOs may be reduced 
due to oxidation and volatilization. Stability and preservation of EOs can be assured with the 
microencapsulation method based on complex coacervation technology. Cyclodextrins are 
suitable as carriers for volatile substances insoluble in water, and hydroxypropyl-β cyclodextrin (HPCD) leads the group considering the aqueous solubility and safe toxicity 
profile. The aim of this study was to find conditions for preparing Oregano and Thyme EOs 
microencapsulates with the best technological properties.Oregano and Thyme EOs were 
encapsulated by the freeze drying (lyophilization) method. Nine different combinations were 
prepared, where HPCD content (10, 15 and 20%) and EO:HPCD mass ratio (1:1, 1:5 and 
1:10) were varied. After stirring (200 rpm) for 24 h at a room temperature, suspensions were 
filtered through 0.45 mm PTFE filters. Samples were evaporated under vacuum and frozen (-
80 °C for 1 h), then main drying was carried out (-60 °C, pressure of 0.011 mbar for 40 h), 
and final drying (-65 °C, pressure of 0.054 mbar for 1 h). To ensure the particle purity, 
lyophilizates were washed with acetonitrile and dried at 25 °C. The content of each EO was 
determined spectrophotometrically, encapsulation efficiency (EE%) and yield were 
calculated. Duncan’s post hoc test was used to evaluate the differences between samples. 
The best conditions for both EOs were obtained with 15% HPCD and EO:HPCD mass ratio 
of 1:10. Yields of EOs for chosen Oregano and Thyme EOs complexes were 86.81 ± 2.20% 
and 89.83 ± 2.80%, respectively, with the following EE% of 49.08 ± 1.80% and 49.29 ± 
0.18%. Microencapsulation is a promising method for improving the EOs stability profile, 
and these results could be very useful in the pharmaceutical and food industry for the 
implementation of new products.
PB  - Belgrade : Institute of Technical Sciences of SASA
C3  - Twentieth Young Researchers Conference – Materials Science and Engineering, November 30 - December 2, 2022, Belgrade, Serbia - Programme and the Book of Abstracts
T1  - Microencapsulation of Oregano and Thyme essential oils with hydroxypropyl-β cyclodextrin
SP  - 14
EP  - 14
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5120
ER  - 

@conference{
author = "Kuzmanović Nedeljković, Snežana and Ćujić Nikolić, Nada and Bigović, Dubravka and Petrović, Predrag and Pljevljakušić, Dejan and Šavikin, Katarina and Filipić, Brankica",
year = "2022",
abstract = "Among plant natural products, Oregano and Thyme essential oils (EOs) are well-known for 
their antimicrobial and antioxidant activity. The biological activities of EOs may be reduced 
due to oxidation and volatilization. Stability and preservation of EOs can be assured with the 
microencapsulation method based on complex coacervation technology. Cyclodextrins are 
suitable as carriers for volatile substances insoluble in water, and hydroxypropyl-β cyclodextrin (HPCD) leads the group considering the aqueous solubility and safe toxicity 
profile. The aim of this study was to find conditions for preparing Oregano and Thyme EOs 
microencapsulates with the best technological properties.Oregano and Thyme EOs were 
encapsulated by the freeze drying (lyophilization) method. Nine different combinations were 
prepared, where HPCD content (10, 15 and 20%) and EO:HPCD mass ratio (1:1, 1:5 and 
1:10) were varied. After stirring (200 rpm) for 24 h at a room temperature, suspensions were 
filtered through 0.45 mm PTFE filters. Samples were evaporated under vacuum and frozen (-
80 °C for 1 h), then main drying was carried out (-60 °C, pressure of 0.011 mbar for 40 h), 
and final drying (-65 °C, pressure of 0.054 mbar for 1 h). To ensure the particle purity, 
lyophilizates were washed with acetonitrile and dried at 25 °C. The content of each EO was 
determined spectrophotometrically, encapsulation efficiency (EE%) and yield were 
calculated. Duncan’s post hoc test was used to evaluate the differences between samples. 
The best conditions for both EOs were obtained with 15% HPCD and EO:HPCD mass ratio 
of 1:10. Yields of EOs for chosen Oregano and Thyme EOs complexes were 86.81 ± 2.20% 
and 89.83 ± 2.80%, respectively, with the following EE% of 49.08 ± 1.80% and 49.29 ± 
0.18%. Microencapsulation is a promising method for improving the EOs stability profile, 
and these results could be very useful in the pharmaceutical and food industry for the 
implementation of new products.",
publisher = "Belgrade : Institute of Technical Sciences of SASA",
journal = "Twentieth Young Researchers Conference – Materials Science and Engineering, November 30 - December 2, 2022, Belgrade, Serbia - Programme and the Book of Abstracts",
title = "Microencapsulation of Oregano and Thyme essential oils with hydroxypropyl-β cyclodextrin",
pages = "14-14",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5120"
}

Kuzmanović Nedeljković, S., Ćujić Nikolić, N., Bigović, D., Petrović, P., Pljevljakušić, D., Šavikin, K.,& Filipić, B.. (2022). Microencapsulation of Oregano and Thyme essential oils with hydroxypropyl-β cyclodextrin. in Twentieth Young Researchers Conference – Materials Science and Engineering, November 30 - December 2, 2022, Belgrade, Serbia - Programme and the Book of Abstracts
Belgrade : Institute of Technical Sciences of SASA., 14-14.
https://hdl.handle.net/21.15107/rcub_farfar_5120

Kuzmanović Nedeljković S, Ćujić Nikolić N, Bigović D, Petrović P, Pljevljakušić D, Šavikin K, Filipić B. Microencapsulation of Oregano and Thyme essential oils with hydroxypropyl-β cyclodextrin. in Twentieth Young Researchers Conference – Materials Science and Engineering, November 30 - December 2, 2022, Belgrade, Serbia - Programme and the Book of Abstracts. 2022;:14-14.
https://hdl.handle.net/21.15107/rcub_farfar_5120 .

Kuzmanović Nedeljković, Snežana, Ćujić Nikolić, Nada, Bigović, Dubravka, Petrović, Predrag, Pljevljakušić, Dejan, Šavikin, Katarina, Filipić, Brankica, "Microencapsulation of Oregano and Thyme essential oils with hydroxypropyl-β cyclodextrin" in Twentieth Young Researchers Conference – Materials Science and Engineering, November 30 - December 2, 2022, Belgrade, Serbia - Programme and the Book of Abstracts (2022):14-14,
https://hdl.handle.net/21.15107/rcub_farfar_5120 .

TY  - CONF
AU  - Kuzmanović Nedeljković, Snežana
AU  - Stević, Tatjana
AU  - Bigović, Dubravka
AU  - Šavikin, Katarina
AU  - Filipić, Brankica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5119
AB  - BACKGROUND
COVID-19 pandemic brought a burden to the health care system including a higher rate of patients admitted to the intensive care unit (ICU). Mechanical ventilation, needed in COVID-19 patients admitted to ICU, increases the risk of developing multidrug-resistant (MDR) Acinetobacter baumannii superinfection, which may cause major problems in antibiotic treatment.
OBJECTIVES
The aim of this research was to examine the susceptibility of A. baumannii isolates recovered from COVID-19 patients 
to antibiotics usually used as treatment options, and to Oregano essential oil (EO) as naturally derived compound.
METHODS 
The 54 A. baumannii isolates were recovered from COVID-19 patients admitted to ICU, during period from December 
2020 to February 2021. Biofilm formation ability, as the factor that contributes to bacterial resistance, was examined. Minimum inhibitory concentrations (MICs) were determined for meropenem, imipenem, colistin, gentamicin, tobramycin and levofloxacin. In addition, all 54 isolates of A. baumanii were tested for susceptibility to Oregano EO.
RESULTS 
Results obtained in this study revealed a significant MDR profile of tested A. baumannii isolates. Even 74% (40/54) were strong biofilm producers. A. baumannii isolates were resistant to all tested antibiotics, except to colistin, leaving colistin as the only treatment option. On the other hand, MIC results obtained for Oregano EO were extremely promising: 0.279 mg/mL for all tested isolates. The obtained results emphasize a potentially new treatment approach to infections caused by MDR A. baumannii, using natural products such as EOs.
PB  - Federation of European Microbiological Societies
PB  - Serbian Society for Microbiology
C3  - FEMS Conference on Microbiology in association with Serbian Society of Microbiology, 30 June - 2 July 2022, Serbia - electronic abstract book
T1  - Oregano essential oil sensitivity of multiresistant Acinetobacter baumannii strains isolated from COVID-19 patients
SP  - 272
EP  - 272
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5119
ER  - 

@conference{
author = "Kuzmanović Nedeljković, Snežana and Stević, Tatjana and Bigović, Dubravka and Šavikin, Katarina and Filipić, Brankica",
year = "2022",
abstract = "BACKGROUND
COVID-19 pandemic brought a burden to the health care system including a higher rate of patients admitted to the intensive care unit (ICU). Mechanical ventilation, needed in COVID-19 patients admitted to ICU, increases the risk of developing multidrug-resistant (MDR) Acinetobacter baumannii superinfection, which may cause major problems in antibiotic treatment.
OBJECTIVES
The aim of this research was to examine the susceptibility of A. baumannii isolates recovered from COVID-19 patients 
to antibiotics usually used as treatment options, and to Oregano essential oil (EO) as naturally derived compound.
METHODS 
The 54 A. baumannii isolates were recovered from COVID-19 patients admitted to ICU, during period from December 
2020 to February 2021. Biofilm formation ability, as the factor that contributes to bacterial resistance, was examined. Minimum inhibitory concentrations (MICs) were determined for meropenem, imipenem, colistin, gentamicin, tobramycin and levofloxacin. In addition, all 54 isolates of A. baumanii were tested for susceptibility to Oregano EO.
RESULTS 
Results obtained in this study revealed a significant MDR profile of tested A. baumannii isolates. Even 74% (40/54) were strong biofilm producers. A. baumannii isolates were resistant to all tested antibiotics, except to colistin, leaving colistin as the only treatment option. On the other hand, MIC results obtained for Oregano EO were extremely promising: 0.279 mg/mL for all tested isolates. The obtained results emphasize a potentially new treatment approach to infections caused by MDR A. baumannii, using natural products such as EOs.",
publisher = "Federation of European Microbiological Societies, Serbian Society for Microbiology",
journal = "FEMS Conference on Microbiology in association with Serbian Society of Microbiology, 30 June - 2 July 2022, Serbia - electronic abstract book",
title = "Oregano essential oil sensitivity of multiresistant Acinetobacter baumannii strains isolated from COVID-19 patients",
pages = "272-272",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5119"
}

Kuzmanović Nedeljković, S., Stević, T., Bigović, D., Šavikin, K.,& Filipić, B.. (2022). Oregano essential oil sensitivity of multiresistant Acinetobacter baumannii strains isolated from COVID-19 patients. in FEMS Conference on Microbiology in association with Serbian Society of Microbiology, 30 June - 2 July 2022, Serbia - electronic abstract book
Federation of European Microbiological Societies., 272-272.
https://hdl.handle.net/21.15107/rcub_farfar_5119

Kuzmanović Nedeljković S, Stević T, Bigović D, Šavikin K, Filipić B. Oregano essential oil sensitivity of multiresistant Acinetobacter baumannii strains isolated from COVID-19 patients. in FEMS Conference on Microbiology in association with Serbian Society of Microbiology, 30 June - 2 July 2022, Serbia - electronic abstract book. 2022;:272-272.
https://hdl.handle.net/21.15107/rcub_farfar_5119 .

Kuzmanović Nedeljković, Snežana, Stević, Tatjana, Bigović, Dubravka, Šavikin, Katarina, Filipić, Brankica, "Oregano essential oil sensitivity of multiresistant Acinetobacter baumannii strains isolated from COVID-19 patients" in FEMS Conference on Microbiology in association with Serbian Society of Microbiology, 30 June - 2 July 2022, Serbia - electronic abstract book (2022):272-272,
https://hdl.handle.net/21.15107/rcub_farfar_5119 .

TY  - JOUR
AU  - Malešević, Milka
AU  - Stanisavljević, Nemanja
AU  - Miljković, Marija
AU  - Jovčić, Branko
AU  - Filipić, Brankica
AU  - Studholme, David
AU  - Kojić, Milan
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3729
AB  - Plasmids are autonomous episomally replicating genetic elements, which carry backbone genes important for the replication and maintenance within their host, and accessory genes that might confer an advantage to their host under specific selective pressure in its ecological niche. The genome of dairy isolate L. lactis subsp. lactis bv. diacetylactis S50 was sequenced using the PacBio SMRT Cell Seq-RSII platform and revealed to possess one of the largest plasmidomes among L. lactis strains studied so far, harboring six plasmids: pS6 (5553 bp), pS7a (7308 bp), pS7b (7266 bp), pS19 (19,027 bp), pS74 (74,256 bp) and pS127 (127,002 bp) in total representing 8.9% of genome size (240,412 bp). Based on predicted plasmid replication proteins and origins it appears that all six plasmids replicate via the theta-type mechanism. The two the largest plasmids (pS74 and pS127), carry a number of genes known to be important for growth and survival in the dairy environment. These genes encode technological functions such as bacteriocin production, protein degradation, magnesium and cobalt/nickel transporters, selenium binding, exopolysaccharides (EPS) production, bacteriophage and stress resistance. Beside genes for replication, the small plasmids (pS6, pS7a, pS7a, and pS19) also carry genes important for mobilization and host survival such as type I restriction-modification (R-M) system, metal transporters, enzymes and transcriptional regulators. All plasmids in S50 strain are mobilizable, containing an oriT sequences, while pS127 is self-conjugative and allows for mobilization of the other plasmids. Small plasmids are prone to structural and segregational instability, while pS127 appeared to be segregationally stable thanks to the possession of two partition systems. The main characteristic of plasmid pS74 is EPS production, while plasmid pS127 is characterized by proteinase and multiple bacteriocins, tra locus, phage abortive systems and metal transporters. In addition to LcnA and LcnB, plasmid pS127 encodes several bacteriocin-pheromone molecules and a new bacteriocin named LcnS50, with narrow spectrum of action limited to lactococci, that has been successfully cloned and heterologously expressed.
PB  - Elsevier B.V.
T2  - International Journal of Food Microbiology
T1  - The large plasmidome of Lactococcus lactis subsp. lactis bv. diacetylactis S50 confers its biotechnological properties
VL  - 337
DO  - 10.1016/j.ijfoodmicro.2020.108935
ER  - 

@article{
author = "Malešević, Milka and Stanisavljević, Nemanja and Miljković, Marija and Jovčić, Branko and Filipić, Brankica and Studholme, David and Kojić, Milan",
year = "2021",
abstract = "Plasmids are autonomous episomally replicating genetic elements, which carry backbone genes important for the replication and maintenance within their host, and accessory genes that might confer an advantage to their host under specific selective pressure in its ecological niche. The genome of dairy isolate L. lactis subsp. lactis bv. diacetylactis S50 was sequenced using the PacBio SMRT Cell Seq-RSII platform and revealed to possess one of the largest plasmidomes among L. lactis strains studied so far, harboring six plasmids: pS6 (5553 bp), pS7a (7308 bp), pS7b (7266 bp), pS19 (19,027 bp), pS74 (74,256 bp) and pS127 (127,002 bp) in total representing 8.9% of genome size (240,412 bp). Based on predicted plasmid replication proteins and origins it appears that all six plasmids replicate via the theta-type mechanism. The two the largest plasmids (pS74 and pS127), carry a number of genes known to be important for growth and survival in the dairy environment. These genes encode technological functions such as bacteriocin production, protein degradation, magnesium and cobalt/nickel transporters, selenium binding, exopolysaccharides (EPS) production, bacteriophage and stress resistance. Beside genes for replication, the small plasmids (pS6, pS7a, pS7a, and pS19) also carry genes important for mobilization and host survival such as type I restriction-modification (R-M) system, metal transporters, enzymes and transcriptional regulators. All plasmids in S50 strain are mobilizable, containing an oriT sequences, while pS127 is self-conjugative and allows for mobilization of the other plasmids. Small plasmids are prone to structural and segregational instability, while pS127 appeared to be segregationally stable thanks to the possession of two partition systems. The main characteristic of plasmid pS74 is EPS production, while plasmid pS127 is characterized by proteinase and multiple bacteriocins, tra locus, phage abortive systems and metal transporters. In addition to LcnA and LcnB, plasmid pS127 encodes several bacteriocin-pheromone molecules and a new bacteriocin named LcnS50, with narrow spectrum of action limited to lactococci, that has been successfully cloned and heterologously expressed.",
publisher = "Elsevier B.V.",
journal = "International Journal of Food Microbiology",
title = "The large plasmidome of Lactococcus lactis subsp. lactis bv. diacetylactis S50 confers its biotechnological properties",
volume = "337",
doi = "10.1016/j.ijfoodmicro.2020.108935"
}

Malešević, M., Stanisavljević, N., Miljković, M., Jovčić, B., Filipić, B., Studholme, D.,& Kojić, M.. (2021). The large plasmidome of Lactococcus lactis subsp. lactis bv. diacetylactis S50 confers its biotechnological properties. in International Journal of Food Microbiology
Elsevier B.V.., 337.
https://doi.org/10.1016/j.ijfoodmicro.2020.108935

Malešević M, Stanisavljević N, Miljković M, Jovčić B, Filipić B, Studholme D, Kojić M. The large plasmidome of Lactococcus lactis subsp. lactis bv. diacetylactis S50 confers its biotechnological properties. in International Journal of Food Microbiology. 2021;337.
doi:10.1016/j.ijfoodmicro.2020.108935 .

Malešević, Milka, Stanisavljević, Nemanja, Miljković, Marija, Jovčić, Branko, Filipić, Brankica, Studholme, David, Kojić, Milan, "The large plasmidome of Lactococcus lactis subsp. lactis bv. diacetylactis S50 confers its biotechnological properties" in International Journal of Food Microbiology, 337 (2021),
https://doi.org/10.1016/j.ijfoodmicro.2020.108935 . .

TY  - JOUR
AU  - Mirković, Nemanja
AU  - Obradović, Mina
AU  - O’Connor, Paula M.
AU  - Filipić, Brankica
AU  - Jovčić, Branko
AU  - Cotter, Paul D.
AU  - Kojić, Milan
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3932
AB  - Screening for producers of potent antimicrobial peptides, resulted in the isolation of Bacillus cereus BGNM1 with strong antimicrobial activity against Listeria monocytogenes. Genome sequence analysis revealed that BGNM1 contains the gene cluster associated with the production of the lantibiotic, thusin, previously identified in B. thuringiensis. Purification of the antimicrobial activity confirmed that strain BGMN1 produces thusin. Both thusin sensitive and resistant strains were detected among clinical isolates of Streptococcus agalactiae. Random mutagenesis of a thusin sensitive strain, S. agalactiae B782, was performed in an attempt to identify the receptor protein for thusin. Three independent thusin resistant mutants were selected and their complete genomes sequenced. Comparative sequence analysis of these mutants with the WT strain revealed that duplication of a region encoding a 79 amino acids repeat in a C-protein α-antigen was a common difference, suggesting it to be responsible for increased resistance to thusin. Since induced thusin resistant mutants showed higher level of resistance than the naturally resistant B761 strain, complete genome sequencing of strain B761 was performed to check the integrity of the C-protein α-antigen-encoding gene. This analysis revealed that this gene is deleted in B761, providing further evidence that this protein promotes interaction of the thusin with receptor.
PB  - Springer Nature
T2  - Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology
T1  - C-protein α-antigen modulates the lantibiotic thusin resistance in Streptococcus agalactiae
VL  - 114
SP  - 1595
EP  - 1607
DO  - 10.1007/s10482-021-01626-3
ER  - 

@article{
author = "Mirković, Nemanja and Obradović, Mina and O’Connor, Paula M. and Filipić, Brankica and Jovčić, Branko and Cotter, Paul D. and Kojić, Milan",
year = "2021",
abstract = "Screening for producers of potent antimicrobial peptides, resulted in the isolation of Bacillus cereus BGNM1 with strong antimicrobial activity against Listeria monocytogenes. Genome sequence analysis revealed that BGNM1 contains the gene cluster associated with the production of the lantibiotic, thusin, previously identified in B. thuringiensis. Purification of the antimicrobial activity confirmed that strain BGMN1 produces thusin. Both thusin sensitive and resistant strains were detected among clinical isolates of Streptococcus agalactiae. Random mutagenesis of a thusin sensitive strain, S. agalactiae B782, was performed in an attempt to identify the receptor protein for thusin. Three independent thusin resistant mutants were selected and their complete genomes sequenced. Comparative sequence analysis of these mutants with the WT strain revealed that duplication of a region encoding a 79 amino acids repeat in a C-protein α-antigen was a common difference, suggesting it to be responsible for increased resistance to thusin. Since induced thusin resistant mutants showed higher level of resistance than the naturally resistant B761 strain, complete genome sequencing of strain B761 was performed to check the integrity of the C-protein α-antigen-encoding gene. This analysis revealed that this gene is deleted in B761, providing further evidence that this protein promotes interaction of the thusin with receptor.",
publisher = "Springer Nature",
journal = "Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology",
title = "C-protein α-antigen modulates the lantibiotic thusin resistance in Streptococcus agalactiae",
volume = "114",
pages = "1595-1607",
doi = "10.1007/s10482-021-01626-3"
}

Mirković, N., Obradović, M., O’Connor, P. M., Filipić, B., Jovčić, B., Cotter, P. D.,& Kojić, M.. (2021). C-protein α-antigen modulates the lantibiotic thusin resistance in Streptococcus agalactiae. in Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology
Springer Nature., 114, 1595-1607.
https://doi.org/10.1007/s10482-021-01626-3

Mirković N, Obradović M, O’Connor PM, Filipić B, Jovčić B, Cotter PD, Kojić M. C-protein α-antigen modulates the lantibiotic thusin resistance in Streptococcus agalactiae. in Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology. 2021;114:1595-1607.
doi:10.1007/s10482-021-01626-3 .

Mirković, Nemanja, Obradović, Mina, O’Connor, Paula M., Filipić, Brankica, Jovčić, Branko, Cotter, Paul D., Kojić, Milan, "C-protein α-antigen modulates the lantibiotic thusin resistance in Streptococcus agalactiae" in Antonie van Leeuwenhoek, International Journal of General and Molecular Microbiology, 114 (2021):1595-1607,
https://doi.org/10.1007/s10482-021-01626-3 . .

TY  - JOUR
AU  - Filipić, Brankica
AU  - Novović, Katarina
AU  - Studholme, David
AU  - Malešević, Milka
AU  - Mirković, Nemanja
AU  - Kojić, Milan
AU  - Jovčić, Branko
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3631
AB  - Long-term overuse of antibiotics has driven the propagation and spreading of antibiotic resistance genes (ARGs) such as efflux pumps in the environment, which can be transferred to clinically relevant pathogens. This study explored the abundance and diversity of ARGs and mobile genetic elements within bacterial communities from sediments of three Western Balkans glacial lakes: Plav Lake (high impact of human population), Black Lake (medium impact of human population) and Donje Bare Lake (remote lake, minimal impact of human population) via shotgun metagenomics. Assembled metagenomic sequences revealed that Resistance-Nodulation-Division (RND) efflux pumps genes were most abundant in metagenome from the Plav Lake. The Integron Finder bioinformatics tool detected 38 clusters of attC sites lacking integron-integrases (CALIN) elements: 20 from Plav Lake, four from Black Lake and 14 from Donje Bare Lake. A complete integron sequence was recovered only from the assembled metagenome from Plav Lake. Plasmid contents within the metagenomes were similar, with proportions of contigs being plasmid-related: 1.73% for Plav Lake, 1.59% for Black Lake and 1.64% for Donje Bare Lake. The investigation showed that RNDs and mobile genetic elements content correlated with human population impact.
PB  - NLM (Medline)
T2  - Journal of water and health
T1  - Shotgun metagenomics reveals differences in antibiotic resistance genes among bacterial communities in Western Balkans glacial lakes sediments
VL  - 18
IS  - 3
SP  - 383
EP  - 397
DO  - 10.2166/wh.2020.227
ER  - 

@article{
author = "Filipić, Brankica and Novović, Katarina and Studholme, David and Malešević, Milka and Mirković, Nemanja and Kojić, Milan and Jovčić, Branko",
year = "2020",
abstract = "Long-term overuse of antibiotics has driven the propagation and spreading of antibiotic resistance genes (ARGs) such as efflux pumps in the environment, which can be transferred to clinically relevant pathogens. This study explored the abundance and diversity of ARGs and mobile genetic elements within bacterial communities from sediments of three Western Balkans glacial lakes: Plav Lake (high impact of human population), Black Lake (medium impact of human population) and Donje Bare Lake (remote lake, minimal impact of human population) via shotgun metagenomics. Assembled metagenomic sequences revealed that Resistance-Nodulation-Division (RND) efflux pumps genes were most abundant in metagenome from the Plav Lake. The Integron Finder bioinformatics tool detected 38 clusters of attC sites lacking integron-integrases (CALIN) elements: 20 from Plav Lake, four from Black Lake and 14 from Donje Bare Lake. A complete integron sequence was recovered only from the assembled metagenome from Plav Lake. Plasmid contents within the metagenomes were similar, with proportions of contigs being plasmid-related: 1.73% for Plav Lake, 1.59% for Black Lake and 1.64% for Donje Bare Lake. The investigation showed that RNDs and mobile genetic elements content correlated with human population impact.",
publisher = "NLM (Medline)",
journal = "Journal of water and health",
title = "Shotgun metagenomics reveals differences in antibiotic resistance genes among bacterial communities in Western Balkans glacial lakes sediments",
volume = "18",
number = "3",
pages = "383-397",
doi = "10.2166/wh.2020.227"
}

Filipić, B., Novović, K., Studholme, D., Malešević, M., Mirković, N., Kojić, M.,& Jovčić, B.. (2020). Shotgun metagenomics reveals differences in antibiotic resistance genes among bacterial communities in Western Balkans glacial lakes sediments. in Journal of water and health
NLM (Medline)., 18(3), 383-397.
https://doi.org/10.2166/wh.2020.227

Filipić B, Novović K, Studholme D, Malešević M, Mirković N, Kojić M, Jovčić B. Shotgun metagenomics reveals differences in antibiotic resistance genes among bacterial communities in Western Balkans glacial lakes sediments. in Journal of water and health. 2020;18(3):383-397.
doi:10.2166/wh.2020.227 .

Filipić, Brankica, Novović, Katarina, Studholme, David, Malešević, Milka, Mirković, Nemanja, Kojić, Milan, Jovčić, Branko, "Shotgun metagenomics reveals differences in antibiotic resistance genes among bacterial communities in Western Balkans glacial lakes sediments" in Journal of water and health, 18, no. 3 (2020):383-397,
https://doi.org/10.2166/wh.2020.227 . .

TY  - JOUR
AU  - Jovčić, Branko
AU  - Novović, Katarina
AU  - Filipić, Brankica
AU  - Velhner, Maja
AU  - Todorović, Dalibor
AU  - Matović, Kazimir
AU  - Rašić, Zoran
AU  - Nikolić, Sonja
AU  - Kiškarolj, Ferenc
AU  - Kojić, Milan
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3760
AB  - The antimicrobial susceptibility testing was conducted on 174 single isolates from poultry farms in Serbia and it was determined that seven Salmonella spp. were multidrug resistant. Sixteen serotypes were detected, but only serotype Infantis confirmed reduced susceptibility to colistin. Seven colistin resistant Salmonella Infantis were studied in detail using the WGS approach. Three sequence types were identified corresponding to different epizootiology region. The isolate from the Province of Vojvodina 3842 and isolates from Jagodina (92 and 821) are represented by the sequence type ST413 and ST11, respectively. Four isolates from Kraljevo are ST32, a common S. Infantis sequence type in humans, poultry and food. The fosfomycin resistance gene fosA7 in isolate 3842 and the vgaA gene in isolate 8418/2948 encoding resistance to pleuromutilins were reported for the first time in serovar Infantis. The changes in relative expression of the phoP/Q, mgrB and pmrA/B genes were detected. Single nucleotide polymorphisms of the pmrB gene, including transitions Val164Gly or Val164Met, and Arg92Pro are described. Analyses of quinolone resistance determining region revealed substitutions Ser83Tyr in GyrA protein and Thr57Ser and Ser80Arg in ParC protein. Based on WGS data, there are two major clusters among analyzed Salmonella Infantis isolates from central Serbia.
PB  - MDPI AG
T2  - Antibiotics
T1  - Genomic characteristics of colistin-resistant salmonella enterica subsp. Enterica serovar infantis from poultry farms in the Republic of Serbia
VL  - 9
IS  - 12
SP  - 1
EP  - 13
DO  - 10.3390/antibiotics9120886
ER  - 

@article{
author = "Jovčić, Branko and Novović, Katarina and Filipić, Brankica and Velhner, Maja and Todorović, Dalibor and Matović, Kazimir and Rašić, Zoran and Nikolić, Sonja and Kiškarolj, Ferenc and Kojić, Milan",
year = "2020",
abstract = "The antimicrobial susceptibility testing was conducted on 174 single isolates from poultry farms in Serbia and it was determined that seven Salmonella spp. were multidrug resistant. Sixteen serotypes were detected, but only serotype Infantis confirmed reduced susceptibility to colistin. Seven colistin resistant Salmonella Infantis were studied in detail using the WGS approach. Three sequence types were identified corresponding to different epizootiology region. The isolate from the Province of Vojvodina 3842 and isolates from Jagodina (92 and 821) are represented by the sequence type ST413 and ST11, respectively. Four isolates from Kraljevo are ST32, a common S. Infantis sequence type in humans, poultry and food. The fosfomycin resistance gene fosA7 in isolate 3842 and the vgaA gene in isolate 8418/2948 encoding resistance to pleuromutilins were reported for the first time in serovar Infantis. The changes in relative expression of the phoP/Q, mgrB and pmrA/B genes were detected. Single nucleotide polymorphisms of the pmrB gene, including transitions Val164Gly or Val164Met, and Arg92Pro are described. Analyses of quinolone resistance determining region revealed substitutions Ser83Tyr in GyrA protein and Thr57Ser and Ser80Arg in ParC protein. Based on WGS data, there are two major clusters among analyzed Salmonella Infantis isolates from central Serbia.",
publisher = "MDPI AG",
journal = "Antibiotics",
title = "Genomic characteristics of colistin-resistant salmonella enterica subsp. Enterica serovar infantis from poultry farms in the Republic of Serbia",
volume = "9",
number = "12",
pages = "1-13",
doi = "10.3390/antibiotics9120886"
}

Jovčić, B., Novović, K., Filipić, B., Velhner, M., Todorović, D., Matović, K., Rašić, Z., Nikolić, S., Kiškarolj, F.,& Kojić, M.. (2020). Genomic characteristics of colistin-resistant salmonella enterica subsp. Enterica serovar infantis from poultry farms in the Republic of Serbia. in Antibiotics
MDPI AG., 9(12), 1-13.
https://doi.org/10.3390/antibiotics9120886

Jovčić B, Novović K, Filipić B, Velhner M, Todorović D, Matović K, Rašić Z, Nikolić S, Kiškarolj F, Kojić M. Genomic characteristics of colistin-resistant salmonella enterica subsp. Enterica serovar infantis from poultry farms in the Republic of Serbia. in Antibiotics. 2020;9(12):1-13.
doi:10.3390/antibiotics9120886 .

Jovčić, Branko, Novović, Katarina, Filipić, Brankica, Velhner, Maja, Todorović, Dalibor, Matović, Kazimir, Rašić, Zoran, Nikolić, Sonja, Kiškarolj, Ferenc, Kojić, Milan, "Genomic characteristics of colistin-resistant salmonella enterica subsp. Enterica serovar infantis from poultry farms in the Republic of Serbia" in Antibiotics, 9, no. 12 (2020):1-13,
https://doi.org/10.3390/antibiotics9120886 . .

TY  - JOUR
AU  - Filipić, Brankica
AU  - Stojić-Vukanić, Zorica
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3565
AB  - Vaccination is one of the most efficient strategies for prevention of infection diseases, but with introduction of sub-unit vaccines with lower immunogenicity adjuvants were needed to enhance the immune response. The term adjuvant is from Latin verb adjuvare which means „to aid”. Adjuvants have been used in vaccines for more than 90 years. The longest adjuvant history belongs to aluminium salts, but novel adjuvants have been introduced in licensed vaccines in last 30 years. These novel adjuvants are AS04, which consists of aluminium hydroxide and Toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A and is used in hepatitis B vaccine Fendrix® and HPV vaccine Cervarix®, emulsion based adjuvants which are part of several influenza vaccines-MF59 (Fluad® and Focetria®) and AS03 (Pandemrix®), AS01 liposomal adjuvant which is combination of two distinct immunostimulatory molecules and is component of herpes zoster and malaria vaccine and virosomes included in hepatits A vaccine (Epaxal®) and influenza vaccines (Inflexal® V and Invivac®). Adjuvant development and better insight into their mechanism of action are of great importance in order to replace empirical with rational use of adjuvants, without affecting vaccine safety.
AB  - Vakcinacija je jedna od najznačajnijih strategija za prevenciju infektivnih oboljenja, a razvoj subjediničnih vakcina doveo je do potrebe za primenom adjuvanasa u vakcinama. Naziv adjuvans potiče od latinske reči adjuvare što znači "pomoći". Adjuvansi su supstance koje se primenjuju u vakcinama više od 90 godina, a dodaju se da bi se povećala imunogenost antigena koji imaju nizak imunostimulatorni potencijal. U vakcinama za primenu kod ljudi, najduže se kao adjuvansi koriste soli aluminijuma, ali je poslednjih decenija nekoliko novih adjuvanasa uključeno u vakcine koje su odobrene za primenu. Adjuvantni sistem AS04, ulazi u sastav vakcina protiv humanog papiloma virusa (Cervarix®) i hepatitis B virusa (Fendrix®) i sadrži aluminijum hidroksid i TLR4 agonist, monofosforil lipid A. Zatim, adjuvansi na bazi emulzije (MF59 i AS03) su sastavni deo vakcina protiv gripa (Fluad®, Focetria® i Pandemrix®). Kombinacija dva imunostimulatorna molekula, označena kao AS01, ulazi u sastav vakcine protiv herpes zoster virusa i malarije dok se adjuvansi na bazi virozoma koriste u vakcinama protiv hepatitisa A (Epaxal®) i gripa (Inflexal® V, Invivac®). Daljim razvojem adjuvanasa, i ispitivanjem njihovog mehanizma delovanja oni će se umesto empirijski, sve više koristili racionalno i ciljano, čime će se postići bolji imunogeni profil vakcina, bez narušavanja njihovog bezbednosnog profila.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Adjuvants in vaccines registered for human use
T1  - Adjuvansi u vakcinama registrovanim    za primenu kod ljudi
VL  - 69
IS  - 6
SP  - 406
EP  - 419
DO  - 10.5937/arhfarm1906406F
ER  - 

@article{
author = "Filipić, Brankica and Stojić-Vukanić, Zorica",
year = "2019",
abstract = "Vaccination is one of the most efficient strategies for prevention of infection diseases, but with introduction of sub-unit vaccines with lower immunogenicity adjuvants were needed to enhance the immune response. The term adjuvant is from Latin verb adjuvare which means „to aid”. Adjuvants have been used in vaccines for more than 90 years. The longest adjuvant history belongs to aluminium salts, but novel adjuvants have been introduced in licensed vaccines in last 30 years. These novel adjuvants are AS04, which consists of aluminium hydroxide and Toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A and is used in hepatitis B vaccine Fendrix® and HPV vaccine Cervarix®, emulsion based adjuvants which are part of several influenza vaccines-MF59 (Fluad® and Focetria®) and AS03 (Pandemrix®), AS01 liposomal adjuvant which is combination of two distinct immunostimulatory molecules and is component of herpes zoster and malaria vaccine and virosomes included in hepatits A vaccine (Epaxal®) and influenza vaccines (Inflexal® V and Invivac®). Adjuvant development and better insight into their mechanism of action are of great importance in order to replace empirical with rational use of adjuvants, without affecting vaccine safety., Vakcinacija je jedna od najznačajnijih strategija za prevenciju infektivnih oboljenja, a razvoj subjediničnih vakcina doveo je do potrebe za primenom adjuvanasa u vakcinama. Naziv adjuvans potiče od latinske reči adjuvare što znači "pomoći". Adjuvansi su supstance koje se primenjuju u vakcinama više od 90 godina, a dodaju se da bi se povećala imunogenost antigena koji imaju nizak imunostimulatorni potencijal. U vakcinama za primenu kod ljudi, najduže se kao adjuvansi koriste soli aluminijuma, ali je poslednjih decenija nekoliko novih adjuvanasa uključeno u vakcine koje su odobrene za primenu. Adjuvantni sistem AS04, ulazi u sastav vakcina protiv humanog papiloma virusa (Cervarix®) i hepatitis B virusa (Fendrix®) i sadrži aluminijum hidroksid i TLR4 agonist, monofosforil lipid A. Zatim, adjuvansi na bazi emulzije (MF59 i AS03) su sastavni deo vakcina protiv gripa (Fluad®, Focetria® i Pandemrix®). Kombinacija dva imunostimulatorna molekula, označena kao AS01, ulazi u sastav vakcine protiv herpes zoster virusa i malarije dok se adjuvansi na bazi virozoma koriste u vakcinama protiv hepatitisa A (Epaxal®) i gripa (Inflexal® V, Invivac®). Daljim razvojem adjuvanasa, i ispitivanjem njihovog mehanizma delovanja oni će se umesto empirijski, sve više koristili racionalno i ciljano, čime će se postići bolji imunogeni profil vakcina, bez narušavanja njihovog bezbednosnog profila.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Adjuvants in vaccines registered for human use, Adjuvansi u vakcinama registrovanim    za primenu kod ljudi",
volume = "69",
number = "6",
pages = "406-419",
doi = "10.5937/arhfarm1906406F"
}

Filipić, B.,& Stojić-Vukanić, Z.. (2019). Adjuvants in vaccines registered for human use. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 69(6), 406-419.
https://doi.org/10.5937/arhfarm1906406F

Filipić B, Stojić-Vukanić Z. Adjuvants in vaccines registered for human use. in Arhiv za farmaciju. 2019;69(6):406-419.
doi:10.5937/arhfarm1906406F .

Filipić, Brankica, Stojić-Vukanić, Zorica, "Adjuvants in vaccines registered for human use" in Arhiv za farmaciju, 69, no. 6 (2019):406-419,
https://doi.org/10.5937/arhfarm1906406F . .

TY  - JOUR
AU  - Filipić, Brankica
AU  - Stojić-Vukanić, Zorica
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3563
AB  - Cancer is one of the leading causes of morbidity and mortality worldwide and great efforts are underway to develop new therapeutic protocols. One of the approaches is immunotherapy which uses the immune system and its components to fight against cancer. The two main axes of cancer immunotherapy refer to passive and active treatments. Passive immunotherapy includes administration of tumor-specific antibodies and autologous T cells which destroy tumor cells, while active immunotherapy is directed at inducing the patient´s own antitumor immune responses and refers to cancer vaccines and immune checkpoint inhibitors. Vaccination of tumor-bearing individuals with tumor cells/antigens or autologous dendritic cells pulsed with tumor antigens may result in enhanced antitumor immune response. However, vaccine design is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery methods and routes of administration need to be precisely defined. Active immunotherapy also addresses the immunosuppressive and tolerogenic mechanisms developed by tumors. This review provides an overview of new results from clinical studies of therapeutic cancer vaccines and discusses their implications for the clinical use, alone or in combination with other immunotherapeutic strategies.
AB  - Maligni tumor (rak, karcinom) je jedan od vodećih uzroka obolevanja i smrtnosti pa se veliki  napori  ulažu  u  razvoj  novih  terapijskih  pristupa.  Savremena  imunoterapija  malignih tumora  obuhvata  primenu  antitumorskih  antitela  i  autologih  T  ćelija  koje  uništavaju  ćelije tumora (pasivna imunoterapija) i pojačanje slabog antitumorskog imunskog odgovora domaćina (aktivna imunoterapija) vakcinacijom i primenom antitela koja blokiraju inhibitorne receptore (kontrolne tačke) T limfocita. Vakcinacija pacijenata obolelih od tumora njihovim sopstvenim tumorskim  ćelijama,  antigenima  tih  ćelija  ili  dendritskim  ćelijama  koje  su  inkubirane  sa tumorskim  antigenima  stimuliše  imunski  sistem  pacijenta  da  prepozna  tumorske  antigene  i eliminiše maligne ćelije. Međutim, razvoj terapijskih tumorskih vakcina suočen je sa brojnim izazovima  vezanim  za  njihov  dizajn,  u  smislu  optimalne  kombinacije  antigena,  adjuvansa  i nosača, kao i za način primene. Pored toga, savremena aktivna imunoterapija treba da prevaziđe nisku imunogenost tumora i imunosupresivne mehanizme mikrosredine tumora kod pacijenata sa klinički ispoljenom bolesti. U ovom radu prikazani su rezultati novijih kliničkih studija u kojima  su  ispitivane  različite  terapijske  vakcine  za  karcinom  i  diskutovano  je  o  njihovoj mogućoj  primeni  u  kliničkoj  praksi,  kako  samih,  tako  i  u  kombinaciji  sa  drugim imunoterapijama.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Active immunotherapy of cancer: An overview of therapeutic vaccines
T1  - Aktivna imunoterapija malignih tumora: pregled terapijskih vakcina
VL  - 69
IS  - 6
SP  - 490
EP  - 506
DO  - 10.5937/arhfarm1906490F
ER  - 

@article{
author = "Filipić, Brankica and Stojić-Vukanić, Zorica",
year = "2019",
abstract = "Cancer is one of the leading causes of morbidity and mortality worldwide and great efforts are underway to develop new therapeutic protocols. One of the approaches is immunotherapy which uses the immune system and its components to fight against cancer. The two main axes of cancer immunotherapy refer to passive and active treatments. Passive immunotherapy includes administration of tumor-specific antibodies and autologous T cells which destroy tumor cells, while active immunotherapy is directed at inducing the patient´s own antitumor immune responses and refers to cancer vaccines and immune checkpoint inhibitors. Vaccination of tumor-bearing individuals with tumor cells/antigens or autologous dendritic cells pulsed with tumor antigens may result in enhanced antitumor immune response. However, vaccine design is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery methods and routes of administration need to be precisely defined. Active immunotherapy also addresses the immunosuppressive and tolerogenic mechanisms developed by tumors. This review provides an overview of new results from clinical studies of therapeutic cancer vaccines and discusses their implications for the clinical use, alone or in combination with other immunotherapeutic strategies., Maligni tumor (rak, karcinom) je jedan od vodećih uzroka obolevanja i smrtnosti pa se veliki  napori  ulažu  u  razvoj  novih  terapijskih  pristupa.  Savremena  imunoterapija  malignih tumora  obuhvata  primenu  antitumorskih  antitela  i  autologih  T  ćelija  koje  uništavaju  ćelije tumora (pasivna imunoterapija) i pojačanje slabog antitumorskog imunskog odgovora domaćina (aktivna imunoterapija) vakcinacijom i primenom antitela koja blokiraju inhibitorne receptore (kontrolne tačke) T limfocita. Vakcinacija pacijenata obolelih od tumora njihovim sopstvenim tumorskim  ćelijama,  antigenima  tih  ćelija  ili  dendritskim  ćelijama  koje  su  inkubirane  sa tumorskim  antigenima  stimuliše  imunski  sistem  pacijenta  da  prepozna  tumorske  antigene  i eliminiše maligne ćelije. Međutim, razvoj terapijskih tumorskih vakcina suočen je sa brojnim izazovima  vezanim  za  njihov  dizajn,  u  smislu  optimalne  kombinacije  antigena,  adjuvansa  i nosača, kao i za način primene. Pored toga, savremena aktivna imunoterapija treba da prevaziđe nisku imunogenost tumora i imunosupresivne mehanizme mikrosredine tumora kod pacijenata sa klinički ispoljenom bolesti. U ovom radu prikazani su rezultati novijih kliničkih studija u kojima  su  ispitivane  različite  terapijske  vakcine  za  karcinom  i  diskutovano  je  o  njihovoj mogućoj  primeni  u  kliničkoj  praksi,  kako  samih,  tako  i  u  kombinaciji  sa  drugim imunoterapijama.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Active immunotherapy of cancer: An overview of therapeutic vaccines, Aktivna imunoterapija malignih tumora: pregled terapijskih vakcina",
volume = "69",
number = "6",
pages = "490-506",
doi = "10.5937/arhfarm1906490F"
}

Filipić, B.,& Stojić-Vukanić, Z.. (2019). Active immunotherapy of cancer: An overview of therapeutic vaccines. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 69(6), 490-506.
https://doi.org/10.5937/arhfarm1906490F

Filipić B, Stojić-Vukanić Z. Active immunotherapy of cancer: An overview of therapeutic vaccines. in Arhiv za farmaciju. 2019;69(6):490-506.
doi:10.5937/arhfarm1906490F .

Filipić, Brankica, Stojić-Vukanić, Zorica, "Active immunotherapy of cancer: An overview of therapeutic vaccines" in Arhiv za farmaciju, 69, no. 6 (2019):490-506,
https://doi.org/10.5937/arhfarm1906490F . .

TY  - JOUR
AU  - Miljković, Marija
AU  - Jovanović, Sofija
AU  - O'Connor, Paula M.
AU  - Mirković, Nemanja
AU  - Jovčić, Branko
AU  - Filipić, Brankica
AU  - Dinić, Miroslav
AU  - Studholme, David John
AU  - Fira, Đorđe
AU  - Cotter, Paul D.
AU  - Kojić, Milan
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3372
AB  - Bacteria active against multi-drug resistant pathogens, isolated by direct selection of colonies from clover silage samples, produce zones of inhibition against two Gram-negative (Klebsiella pneumoniae Ni9 and Pseudomonas aeruginosa MMA83) and two Gram-positive (Staphylococcus aureus ATCC25923 and Listeria monocytogenes ATCC19111) pathogens. Isolates BGSP7, BGSP9, BGSP11 and BGSP12 produced the largest zones of inhibition against all four pathogens when grown in LB broth with aeration at 37 degrees C. Isolates BGSP7, BGSP9, BGSP11 and BGSP12 were identified as Brevibacillus laterosporus and pulsed field gel electrophoresis and extracellular protein profiles showed that three different strains (BGSP7, BGSP9 and BGSP11) were isolated. A semi-native SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) gel overlay assay showed that BGSP7 and BGSP9 produce small antimicrobial molecules of about 1.5 kDa, while BGSP11 produces antimicrobial molecules of 1.5 and 6 kDa active against S. aureus ATCC25923. Amino acid analysis of two antimicrobial molecules (1583.73 Da; from BGSP7 and 1556.31 Da; from BGSP11) revealed that they have a similar composition and differ only by virtue of the presence of a methionine which is present only in BGSP11 molecule. Genome sequencing of the three isolates revealed the presence of gene clusters associated with the production of non-ribosomally synthesized peptides (brevibacillin, bogorol, gramicidin S, plipastatin and tyrocin) and bacteriocins (laterosporulin, a lactococcin 972-like bacteriocin, as well as putative linocin M18, sactipeptide, UviB and lantipeptide-like molecules). Ultimately, the purification of a number of antimicrobial molecules from each isolate suggests that they can be considered as potent biocontrol strains that produce an arsenal of antimicrobial molecules active against Gram-positive and Gram-negative multi-resistant pathogens, fungi and insects.
PB  - Public Library Science, San Francisco
T2  - PLoS One
T1  - Brevibacillus laterosporus strains BGSP7, BGSP9 and BGSP11 isolated from silage produce broad spectrum multi-antimicrobials
VL  - 14
IS  - 5
DO  - 10.1371/journal.pone.0216773
ER  - 

@article{
author = "Miljković, Marija and Jovanović, Sofija and O'Connor, Paula M. and Mirković, Nemanja and Jovčić, Branko and Filipić, Brankica and Dinić, Miroslav and Studholme, David John and Fira, Đorđe and Cotter, Paul D. and Kojić, Milan",
year = "2019",
abstract = "Bacteria active against multi-drug resistant pathogens, isolated by direct selection of colonies from clover silage samples, produce zones of inhibition against two Gram-negative (Klebsiella pneumoniae Ni9 and Pseudomonas aeruginosa MMA83) and two Gram-positive (Staphylococcus aureus ATCC25923 and Listeria monocytogenes ATCC19111) pathogens. Isolates BGSP7, BGSP9, BGSP11 and BGSP12 produced the largest zones of inhibition against all four pathogens when grown in LB broth with aeration at 37 degrees C. Isolates BGSP7, BGSP9, BGSP11 and BGSP12 were identified as Brevibacillus laterosporus and pulsed field gel electrophoresis and extracellular protein profiles showed that three different strains (BGSP7, BGSP9 and BGSP11) were isolated. A semi-native SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) gel overlay assay showed that BGSP7 and BGSP9 produce small antimicrobial molecules of about 1.5 kDa, while BGSP11 produces antimicrobial molecules of 1.5 and 6 kDa active against S. aureus ATCC25923. Amino acid analysis of two antimicrobial molecules (1583.73 Da; from BGSP7 and 1556.31 Da; from BGSP11) revealed that they have a similar composition and differ only by virtue of the presence of a methionine which is present only in BGSP11 molecule. Genome sequencing of the three isolates revealed the presence of gene clusters associated with the production of non-ribosomally synthesized peptides (brevibacillin, bogorol, gramicidin S, plipastatin and tyrocin) and bacteriocins (laterosporulin, a lactococcin 972-like bacteriocin, as well as putative linocin M18, sactipeptide, UviB and lantipeptide-like molecules). Ultimately, the purification of a number of antimicrobial molecules from each isolate suggests that they can be considered as potent biocontrol strains that produce an arsenal of antimicrobial molecules active against Gram-positive and Gram-negative multi-resistant pathogens, fungi and insects.",
publisher = "Public Library Science, San Francisco",
journal = "PLoS One",
title = "Brevibacillus laterosporus strains BGSP7, BGSP9 and BGSP11 isolated from silage produce broad spectrum multi-antimicrobials",
volume = "14",
number = "5",
doi = "10.1371/journal.pone.0216773"
}

Miljković, M., Jovanović, S., O'Connor, P. M., Mirković, N., Jovčić, B., Filipić, B., Dinić, M., Studholme, D. J., Fira, Đ., Cotter, P. D.,& Kojić, M.. (2019). Brevibacillus laterosporus strains BGSP7, BGSP9 and BGSP11 isolated from silage produce broad spectrum multi-antimicrobials. in PLoS One
Public Library Science, San Francisco., 14(5).
https://doi.org/10.1371/journal.pone.0216773

Miljković M, Jovanović S, O'Connor PM, Mirković N, Jovčić B, Filipić B, Dinić M, Studholme DJ, Fira Đ, Cotter PD, Kojić M. Brevibacillus laterosporus strains BGSP7, BGSP9 and BGSP11 isolated from silage produce broad spectrum multi-antimicrobials. in PLoS One. 2019;14(5).
doi:10.1371/journal.pone.0216773 .

Miljković, Marija, Jovanović, Sofija, O'Connor, Paula M., Mirković, Nemanja, Jovčić, Branko, Filipić, Brankica, Dinić, Miroslav, Studholme, David John, Fira, Đorđe, Cotter, Paul D., Kojić, Milan, "Brevibacillus laterosporus strains BGSP7, BGSP9 and BGSP11 isolated from silage produce broad spectrum multi-antimicrobials" in PLoS One, 14, no. 5 (2019),
https://doi.org/10.1371/journal.pone.0216773 . .

TY  - JOUR
AU  - Novović, Katarina
AU  - Malesević, Milka
AU  - Filipić, Brankica
AU  - Mirković, Nemanja
AU  - Miljković, Marija
AU  - Kojić, Milan
AU  - Jovčić, Branko
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3313
AB  - Pseudomonas aeruginosa, which is a clinically important representative of Pseudomonas spp., has been recognized as causative agent of severe nosocomial infections worldwide. An increase in antibiotic resistance of P. aeruginosa clinical strains could be attributed to their capacity to acquire resistance through mobile genetic elements such as mobile integrons that are present in one-half of multidrug-resistant P. aeruginosa strains. Mobile class 1 integrons are recognized as genetic elements involved in the rapid dissemination of multiple genes encoding for antibiotic resistance. The LexA protein is a major repressor of integrase transcription, but differences in transcription regulation among bacterial species have also been noted. In this study, the promoter activity of class 1 integron integrase gene (intI1) and its variant lacking the LexA binding site in Pseudomonas putida WCS358 wild type, rpoS and psrA was analysed. The results show that the activity of the intI1 gene promoter decreased in the rpoS and psrA mutants in the stationary phase of growth compared to the wild type, which indicates the role of RpoS and PsrA proteins in the positive regulation of integrase transcription. Additionally, it was determined that the activity of the lexA gene promoter decreased in rpoS and psrA, and thus, we propose that PsrA indirectly regulates the intI1 gene promoter activity through regulation of lexA gene expression in co-operation with some additional regulators. In this study, intI1 gene expression was shown to be controlled by two major stress response (SOS and RpoS) regulons, which indicates that integrase has evolved to use both systems to sense the cell status.
PB  - Springer, New York
T2  - Current Microbiology
T1  - PsrA Regulator Connects Cell Physiology and Class 1 Integron Integrase Gene Expression Through the Regulation of lexA Gene Expression in Pseudomonas spp.
VL  - 76
IS  - 3
SP  - 320
EP  - 328
DO  - 10.1007/s00284-019-01626-7
ER  - 

@article{
author = "Novović, Katarina and Malesević, Milka and Filipić, Brankica and Mirković, Nemanja and Miljković, Marija and Kojić, Milan and Jovčić, Branko",
year = "2019",
abstract = "Pseudomonas aeruginosa, which is a clinically important representative of Pseudomonas spp., has been recognized as causative agent of severe nosocomial infections worldwide. An increase in antibiotic resistance of P. aeruginosa clinical strains could be attributed to their capacity to acquire resistance through mobile genetic elements such as mobile integrons that are present in one-half of multidrug-resistant P. aeruginosa strains. Mobile class 1 integrons are recognized as genetic elements involved in the rapid dissemination of multiple genes encoding for antibiotic resistance. The LexA protein is a major repressor of integrase transcription, but differences in transcription regulation among bacterial species have also been noted. In this study, the promoter activity of class 1 integron integrase gene (intI1) and its variant lacking the LexA binding site in Pseudomonas putida WCS358 wild type, rpoS and psrA was analysed. The results show that the activity of the intI1 gene promoter decreased in the rpoS and psrA mutants in the stationary phase of growth compared to the wild type, which indicates the role of RpoS and PsrA proteins in the positive regulation of integrase transcription. Additionally, it was determined that the activity of the lexA gene promoter decreased in rpoS and psrA, and thus, we propose that PsrA indirectly regulates the intI1 gene promoter activity through regulation of lexA gene expression in co-operation with some additional regulators. In this study, intI1 gene expression was shown to be controlled by two major stress response (SOS and RpoS) regulons, which indicates that integrase has evolved to use both systems to sense the cell status.",
publisher = "Springer, New York",
journal = "Current Microbiology",
title = "PsrA Regulator Connects Cell Physiology and Class 1 Integron Integrase Gene Expression Through the Regulation of lexA Gene Expression in Pseudomonas spp.",
volume = "76",
number = "3",
pages = "320-328",
doi = "10.1007/s00284-019-01626-7"
}

Novović, K., Malesević, M., Filipić, B., Mirković, N., Miljković, M., Kojić, M.,& Jovčić, B.. (2019). PsrA Regulator Connects Cell Physiology and Class 1 Integron Integrase Gene Expression Through the Regulation of lexA Gene Expression in Pseudomonas spp.. in Current Microbiology
Springer, New York., 76(3), 320-328.
https://doi.org/10.1007/s00284-019-01626-7

Novović K, Malesević M, Filipić B, Mirković N, Miljković M, Kojić M, Jovčić B. PsrA Regulator Connects Cell Physiology and Class 1 Integron Integrase Gene Expression Through the Regulation of lexA Gene Expression in Pseudomonas spp.. in Current Microbiology. 2019;76(3):320-328.
doi:10.1007/s00284-019-01626-7 .

Novović, Katarina, Malesević, Milka, Filipić, Brankica, Mirković, Nemanja, Miljković, Marija, Kojić, Milan, Jovčić, Branko, "PsrA Regulator Connects Cell Physiology and Class 1 Integron Integrase Gene Expression Through the Regulation of lexA Gene Expression in Pseudomonas spp." in Current Microbiology, 76, no. 3 (2019):320-328,
https://doi.org/10.1007/s00284-019-01626-7 . .